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ABSTRACT 
Klotho (KL), an anti-aging protein, attracted interest in the aging field 
because of the dramatic phenotype of KL deficient mice and its connection to 
signaling pathways implicated in aging.  The KLVS variant consists of the F352V 
(KLV) and C370S (KLS) substitutions. It was detected in genome wide 
association studies (GWAS) that linked it to alterations in longevity and disease 
risk. The molecular mechanism(s) underlying these associations are unknown. To 
understand how KL increases the risk of age-related diseases, the studies in this 
dissertation investigated whether expression of the KLVS variant, when 
compared to wildtype (KLWT), displays differences in processing, protein-
protein interactions and enzymatic activity.  
 Differences in processing were evaluated by studying changes in 
shedding, half-life and plasma membrane localization of KL variants.  The 
decrease in KLV shedding, as measured by the intracellular: extracellular ratio, 
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were explained by a decreased half-life. This decreased half-life is potentially due 
to decreased KLV plasma membrane localization, which is attenuated by co-
expression of dominant negative dynamin, suggesting a role of endocytosis in 
these differences.  
To assess whether there are changes in KLVS protein-protein interactions, 
differences in dimerization were measured by Blue Native gel electrophoresis and 
cross-linking. KLV dimerization was increased while KLS and KLVS variants 
decreased dimerization. Co-immunoprecipitation of tagged KL assessed whether 
these changes were due to alterations in homodimerization. The presence of 
KLVS in dimers decreased the levels of immunoprecipitated KL suggesting KLVS 
decreases homodimerization.     
Changes in heterodimerization of KLVS with fibroblast growth factor 
receptor (FGFR) 1c were also investigated through co-immunoprecipitation. 
KLVS increased heterodimerization with FGFR1c.  Addition of FGF23, for which 
KL is a co-receptor, showed that KLVS increases FGF signaling downstream of 
FGFR1c.   
To determine differences in enzymatic activity of KLVS, 4-
metylumbelliferyl-beta-D-glucuronide was used to measure alterations in 
glucuronidase activity. Results showed that KLVS had decreased enzymatic 
activity compared to KLWT. 
 These findings are the first to show that KLVS leads to differences in 
function as demonstrated by decreased homodimerization and enzymatic activity 
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and increased heterodimerization with FGFR1c.  Given the association of KLVS 
with disease and longevity, these results suggest that these functions are integral 
in KL’s anti-aging role in humans. 
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CHAPTER I: INTRODUCTION 
1. THEORIES OF AGING 
1.1 General Introduction 
Over the years, advances in preventative medicine and progress in the 
treatment of the major killers such as heart disease, stroke and cancer, have led 
to an increase in the percentage of the United States population over the age of 
65.  From the years 1960 to 1990 alone, there was an 86.67% increase in this 
group compared to the 38.7% overall increase in the population.  When this 
comparison is confined to people who are over 85, the difference is even greater.  
This group saw an increase of 225.2% over this 30-year period (1).  Despite our 
increased ability to prolong life and delay the onset of many diseases, we still do 
not have a good understanding of the underlying causes of aging.  Until we have a 
better grasp of what causes aging, we will be able to delay, but not prevent the 
many diseases for which aging is a major risk factor.  Although we have found 
ways to prolong the healthy years, eventually most people succumb to disease, 
which leads to a heavy strain on healthcare and other systems that have to 
support the people that can no longer care for themselves.  Although disease 
prevention is an admirable goal, targeting just one disease at a time will only lead 
to small incremental differences in lifespan. Even curing cancer, which is one of 
the leading causes of death in the US(2), would only lead to a 3-year extension of 
life expectancy. By targeting and understanding the underlying mechanisms of 
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aging instead, we could better grasp the underlying causes of these diseases 
leading to a healthier aging population.  
Intense study of the mechanisms of aging is fairly new, but despite that, 
many have attempted to create theories in order to explain why organisms age. In 
fact, in the relatively short time since the first theory was posited in 1889, there 
have been more than 300 theories of aging (3).  Most have merit and explain an 
important aspect of aging, but due to the complexities of aging, the answer will 
not be found solely in one theory. Developing a global understanding of the 
posited theories from past and present help to not only understand how the field 
has matured, but also to appreciate how they come together to help us reach 
towards the ultimate goal of elucidating how and why organisms age.  
 
1.2. Evolutionary Theories  
1.2.1 Aging Theory of Natural Selection 
One of the first theories of aging posited in the 1940’s built on ideas from 
natural selection.  This theory suggested that forces of natural selection decline 
with age resulting in selection of genes that are beneficial for early survival and 
reproduction but detrimental for longevity.  This theory was first advanced after 
observations on the pervasiveness of Huntington’s disease.  It was thought that a 
dominant lethal gene such as Huntingtin should be selected against, but because 
of its later onset (after child-bearing age) there was no selective pressure against 
it (4).  Another contemporary scientist expounded upon this idea leading to the 
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Mutation Accumulation Theory of aging.  This theory suggested senescence and 
aging associated pathology may be caused by the accumulation of late-acting 
detrimental mutations that escape natural selection due to time of onset (5).  This 
was further built upon by G.C. Williams, who came up with the idea of 
antagonistic pleiotropy, he proposed that late-acting detrimental mutations could 
be selected for if they caused beneficial pleiotropic effects in early life (6).  
Although the mutation accumulation theory is not currently widely backed (7), 
these early theories spurred a plethora of research into the role natural selection 
plays in aging.  
Research that was built upon the early theories of aging has shown that 
natural selection can play a role in how organisms age.  Not only does selection of 
offspring derived from longer-lived parents lead to an increase in lifespan in 
drosophila (8,9), but different environmental conditions of opossums also altered 
their lifespan.  When compared to opossums that live in areas of high predation, 
island opossums that were protected from predators lived longer and aged more 
slowly than their mainland counterparts (10).  This suggests that natural 
selection due to predation and environmental conditions can affect the longevity 
of organisms.  
 
1.2.2 Disposable Soma Hypothesis 
One hypothesis that expanded upon the idea of antagonistic pleiotropy, 
the disposable soma hypothesis, suggested that selection favors genes that 
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increase reproductive fitness regardless of its effect on long-term survival (11).  It 
posited that in the tradeoff between energy invested into reproduction, somatic 
maintenance and survival, selection favors the traits that allow for increased 
reproductive fitness.  More recent theories that have examined the origin of aging 
suggest that asymmetric cell division in unicellular organisms leads to an uneven 
distribution of accumulated mutations.  By unevenly distributing structures into 
one progeny, the second progeny must make new structures that do not contain 
any of the accumulated damage resulting in the creation of one ‘rejuvenated’ 
offspring and one ‘parent’ cell that contains all the damage.  If damage 
accumulation is high enough, this asymmetrical division can lead to progeny with 
a higher chance of survival than those obtained by symmetrical division. This 
asymmetrical division leads to the aging ‘parent’ population that has slowed 
division and growth rate and the ‘rejuvinated’ offspring population.  Before this 
research it was though that aging arose after the origin of eukaryotes, but this 
research suggests that it may have arose earlier and might be the underpinnings 
of the evolutionary reasons for aging (12).   
These theories focus on the genetic origins of aging and longevity, which 
help us to understand why aging may have developed, but lack mechanistic 
insight into how the changes in genes lead to the phenotypes we see. 
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1.3 Oxidative Stress and Aging 
1.3.1 Free Radical Theory  
The free radical theory of aging was posited shortly after the debut of the 
first evolutionary theories in the 1950’s.  Inspired by Gerschman’s observations 
on oxygen poisoning (13), Harman hypothesized that environmental and genetic 
factors lead to the accumulation of harmful oxygen radicals in cells producing the 
damage that causes aging and eventually death of organisms (14).  This theory 
was further modified in lieu of new information about the importance of 
mitochondria in the initiation of most free radical reactions (15,16).  The 
ubiquitous nature of free radicals makes the free radical theory a popular 
explanation of how and why organisms age.  In eukaryotes specifically, 
mitochondrial respiration, which is necessary for energy production, is 
responsible for leaking free radical intermediates from the electron transport 
chain (17).  Not only is the presence of free radicals and the scavengers 
responsible for their clearing universal, but the targets of free radicals are also 
widespread (18).  Oxidative damage can affect most of the major players in cells: 
DNA, protein and lipid molecules (19) and this damage has been shown to 
accumulate in protein (20-22) and DNA (23-25) with age.  
Despite evidence that oxidative damage accumulates with age, much of the 
evidence of its involvement in the aging process is limited to lower eukaryotes. 
Drosophila with increased superoxide dismutase expression led longer lives 
(26,27) and flies selected for longer lifespan showed increased levels of this 
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enzyme (28). Studies in C. elegans have also shown long-lived mutants are 
resistant to oxidative stress and have increased activity of superoxide scavengers 
with age (29). C. elegans longevity can also be increased artificially by 
compounds that mimic superoxide dismutase or other antioxidant molecules 
(30).   
Unlike lower eukaryotes, modification of lifespan by regulation of 
oxidative stress in mammals has not been as straightforward.  Overexpression of 
superoxide dismutase was not capable of modifying lifespan (31) and dietary 
administration of antioxidants to rodents has led to inconclusive results on its 
ability to modify lifespan (32).  The unclear results of antioxidant administration 
could be due to differences in length of treatment (33) or differences in the 
outcome measured.  Although treatments do not always have a direct effect on 
maximum lifespan, they can have an effect on quality of life as measured by 
organ and organelle health (32,34-39).  
Oxidative damage is widely accepted as a contributing factor in the aging 
process despite the lack of effective treatments using antioxidants.  Many groups 
have shown oxidized protein accumulate with age, which supports its connection 
to aging (40).  Many pathways that protect against organism aging, which are 
discussed in detail later, also act by protecting against oxidative stress further 
implicating oxidative stress as a key player in the aging phenotype.  
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1.3.2 Mitochondrial Theory 
Stemming from the reactive oxygen theory of aging, the mitochondrial 
theory concentrates on the importance of mitochondria not only in the 
generation of reactive oxygen species, but also on its role in maintenance of cell 
health and physiology (41).  Despite the crucial role mitochondria play in cell 
health, they are susceptible to damage by reactive oxygen species.  It is estimated 
that levels of oxidation in mitochondrial DNA are 10 to 20 fold higher than that 
of nuclear DNA due to the mitochondria’s role in oxygen metabolism as well as its 
lack of histones and less efficient DNA repair (24,42).  This higher rate of 
mutation creates a vicious cycle because of the mitochondria’s role in the electron 
transport chain.  Not only is it the source of many oxygen radicals, but 
mitochondrial DNA is responsible for encoding many of the proteins that make 
up the electron transport chain as well as proteins necessary for their synthesis 
(43).  This means that damage to these genes can lead to further disruption of the 
electron transport chain potentially leading to additional alterations in levels of 
reactive oxygen species.  
There is a lot of indirect evidence linking mitochondria to aging, including 
findings by the Framingham Heart Study that have shown lifespan is more 
strongly correlated with maternal than paternal death, suggesting that 
mitochondria may play a role in lifespan determination (44).  Other studies have 
reported a correlation between mitochondrial DNA polymorphisms and longevity 
(45-47).  Some groups have also shown that increasing rates of mutation in 
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mitochondrial DNA leads to the display of features suggestive of premature aging 
(48-50). Decreasing mitochondrial damage due to oxidative stress leads to the 
opposite effect, increasing the lifespan of mice overexpressing catalase in 
mitochondria (51).  This research supports an indirect role of mitochondrial 
function in the aging process through its regulation of electron transport and 
metabolism.  Despite these connections, more information is necessary to 
determine how intricately involved the mitochondria is in the process of aging.  
 
1.4 DNA Damage and Aging 
1.4.1 Gene Regulation Theory  
 The gene regulation theory of aging posits that senescence is the product 
of changes in gene expression that occur over time (52).  Microarray studies have 
found many genes that are differentially expressed with age (39,53-60).  
Reminiscent of the evolutionary theory of aging, it has been suggested that the 
genes that are differentially regulated by age are not likely to be genes that 
directly regulate senescence, but actually those that regulate survival (61).  This 
distinction is necessary to help remind us that aging itself is not a programmed 
process, but is stochastic and not directly regulated.  Despite this, twin studies in 
humans suggest there is a small albeit significant genetic component of lifespan 
(62,63).  Studies in centenarians have also shown some genetic associations (64-
66) and recently a locus of chromosome 4 has been linked to the longevity effects 
seen in this group (67).  
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 It is known that genes are altered both directly and epigenetically in aging 
and it is possible that these alterations can lead to changes in their expression 
thus causing more age-related effects.  Werner’s syndrome, which causes 
progeria, gives insight into how gene recombination leads to changes in gene 
expression that can regulate aging.  The WRN gene that is altered in this 
syndrome suppresses genome instability and homologous recombination (68,69) 
suggesting that dysregulation of recombination can lead to aging symptoms.  
Further evidence for the importance of gene recombination comes from mouse 
models that have defects in genome maintenance systems that protect against 
large genome rearrangements.  Mice deficient in these areas have high levels of 
recombination and present with a variety of accelerated aging phenotypes 
(70,71).  Levels of DNA methylation (72-74) and patterns of methylation have 
both been reported to change with age (75-78) and these changes can lead to 
alterations in the amount of specific genes transcribed (75,77-80).  Changing the 
expression levels of genes could lead to alterations in cell function and contribute 
to the senescent phenotype seen with age. 
 Identification of the insulin/insulin like growth factor (IGF) 1 pathway’s 
involvement in aging further suggests that gene regulation can affect aging.  This 
pathway was first implicated in C. elegans where it was shown that worms with 
mutations in the insulin-like dauer formation pathway, lived longer (81).  This 
research was followed by studies in mice showing that heterozygous knockdown 
of the IGF-1 receptor led to an increase in lifespan (82). This increase in lifespan 
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is thought to be connected to the regulation of transcription factors such as shc 
and Forkead box O (FOXO), which can also regulate lifespan in mice (83) (84).  
These transcription factors lead to the upregulation of antioxidant proteins 
showing a connection between the gene regulation theory and the free radical 
theory of aging.  
 Despite the connections to the insulin/IGF-1 pathway, many models of 
increased mouse longevity, including the fairly robust model of caloric 
restriction, are shown to have increased insulin sensitivity suggesting that there 
may be more Insulin/IGF-1 signaling (85).  Although this further implicates this 
pathway in longevity and aging, the direction of influence is counter-intuitive 
given the effects of inhibiting the insulin pathway.  This suggests that the 
interaction of insulin and IGF-1 with aging is more complex than is currently 
appreciated and must be studied further to understand the relationship.    
 The studies into the Gene Regulation Theory of aging provide multiple 
series of evidence suggesting that regulation of genes is involved in the aging 
process, but our understanding of aging and natural selection remind us that 
aging may not be directly regulated by these changes in gene expression.  The full 
complexity of the relationship between gene expression changes and aging is not 
completely understood as small differences in gene transcription can lead to large 
downstream changes in protein expression.  More investigation of the Gene 
Regulation Theory will elucidate how the changes in gene expression tie in to 
other theories of aging leading to the global effect seen in aging organisms. 
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1.4.2 Senescence/Telomere Theory 
The theory of senescence stemmed from early observations in cultured 
cells demonstrating that these cells had a replicative limit (86,87).  Hayflick and 
colleagues expanded upon these findings proposing what is now referred to as the 
senescence theory of aging.  He described senescence through his observations 
that human cells in culture undergo a limited number of divisions after which cell 
growth was arrested and the physiology of the cells was altered.  
Further research determined that the replicative senescence described is 
often due to shortening of telomeres, specialized DNA repeats found at the end of 
chromosomes.  In human cells, telomeres are shortened during mitosis due to 
suppression of telomerase expression that is responsible for maintaining 
telomere length (88).  Shortening of telomeres eventually leads to a DNA damage 
response that initiates senescence (89-93).  Conversely, cells lines that express 
telomerase do not senesce, but continue to proliferate normally (94-96).  
Senescence can also be initiated by stress responses that include inappropriate 
nutrient conditions and oxidative stress (97-100).  In most cases these are not 
associated with the same DNA damage response that occurs with telomere-
associated senescence, but there are reports of oxidative damage causing 
telomere shortening (101).  The development of the senescence growth arrest 
phenotype upon cell stress or DNA damage supports the role of antagonistic 
pleiotropy in aging.  While it is though to have arisen as anti-tumorigenic 
mechanism, it also has an affect in aging organisms. 
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Evidence for involvement of senescence in aging can be seen both in 
animal models and human tissues.  Mice that express a constitutively active 
truncated protein 53 (p53) display a number of aging phenotypes culminating in 
a shortened lifespan (102,103).  The transcription factor p53 is known to be a 
master regulator of senescence (104-107) and cells in vivo and in vitro from mice 
expressing the truncated form of the protein senesced rapidly (103,108), 
suggesting that the alteration in senescence is responsible for the aging effects.  
Other mice models that induce senescence also lead to pathologies resembling 
advanced aging (109-111).  There is also evidence from human tissues showing 
that increased age of the tissue donor is correlated with a decreased capacity for 
population doubling (112-118).  This suggests that older tissues have accelerated 
rates of senescence even when transplanted into younger hosts, although other 
studies show that parabiosis of young and old mice can influence the apparent 
age of both brain and heart tissue arguing that circulating factors are capable of 
modulating the aging phenotype (119,120).  Further support for the involvement 
of senescence in human aging comes from data showing that shortened telomeres 
accumulate with age in human cell lines and tissues (121-123).  Levels of β-
galactosidase, a marker of in vitro senescence, also had increased expression with 
age (124) further pointing to an increase of senescence with age.  All of this points 
to a role of senescence, either through telomere shortening or other means in the 
aging process.  
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1.5 System Based Theories of Aging 
1.5.1 Network Theory 
The network or immune theory of aging builds upon previous theories 
concentrating on the network of defense mechanisms in the cell that indirectly 
control aging (125).  This network consists of a variety of mechanisms, namely 
DNA repair, production of heat shock and other stress proteins, enzymatic and 
non-enzymatic antioxidant defense systems, poly (ADP-ribose) polymerase 
activation and the immune system that have developed to protect cells from 
internal and external stressors (125).  This theory explains differences in lifespan 
by the fact that the aforementioned mechanisms involved in the network are 
controlled by genes that have varying inter-species and intra-species expression 
levels (126).  This intertwines the immune theory with previously mentioned 
theories suggesting a role of gene expression in aging.  
The immune system, in particular macrophages, are highly implicated as 
playing a central role in the network of defense mechanisms (127).  Macrophages’ 
ability to respond to a multitude of different stress signals by releasing many 
different factors including cytokines, biogenic amines and neuropeptides make it 
a key regulator of the immune system and by proxy, the aging process (127).  The 
results of many studies suggest that macrophage function and ability to respond 
to tissue-derived signals is impaired during aging (128-133), leading to an overall 
impaired immune response (134).  Besides macrophages, other immune cell 
types have been implicated in aging.  Lymphocytes, for example, are chronically 
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stimulated leading to an expansion of memory cells, decrease of naïve cells and 
shrinkage of the T cell repertoire with age (135-138).   
To support the theory that the immune system is an important regulator of 
aging, it has been shown that maintenance of a healthy immune system is 
correlated with increased longevity (139).  Additional evidence comes from 
studies in centenarians and long-lived individuals that demonstrate these 
populations have immune system comparable to young controls versus the 
decrease in function seen in normal elderly subjects (139-143), further 
implicating the immune system in the regulation of aging. 
The importance of the network/immune theory is strengthened by its 
connections with other theories, including the free radical theory.  Antioxidants 
are found in higher concentrations in immune cells suggesting dysregulation of 
this system with age could result in more oxidative stress due to fewer scavengers 
present.  Antioxidants are also important for maintenance of proper immune 
system function (144) so it is possible that the increases in free radicals with age 
could lead to the dysfunction of the immune system.  The network/immune 
theory also ties back to the evolutionary theory of aging because of the 
importance of the immune system in survival.  Like many genes/ pathways that 
affect aging, the immune system is important for survival in early age, but in 
dysregulation in later stages it can be detrimental to the organism.  
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1.5.2 Inflammation Hypothesis 
The inflammation hypothesis is directly connected to the 
network/immune theory of aging, but emphasizes the upregulation of 
inflammation in later life that leads to the chronic inflammatory state associated 
with many diseases (145-148).  This “inflamm-aging”, as it has been coined (127), 
is the result of environmental stimuli and innate aging processes that lead to 
increased levels of pro-inflammatory cytokines (149-152) upsetting the balance 
between pro- and anti-inflammatory signals.  The effects of polymorphisms that 
act upon these pathways demonstrate that altering levels of pro- and anti-
inflammatory cytokines can alter longevity (153-156).   
Like the network/immune theory of aging, this hypothesis ties in many 
different theories to start making a more coherent picture of how these multiple 
changes may lead to the global phenotype of aging.  One theory to which the 
inflammation hypothesis is closely tied is the senescence/telomere theory. 
Senescent cells secrete pro-inflammatory cytokines in a process known as the 
senescence-associated secretory phenotype (SASP).  This suggests that the 
increase in senescence associated with age can also lead to an increase in 
inflammation, which may be related to the inflammatory phenotype seen in 
aging.  This theory, along with the network/immune theory, show how 
interconnected the different aging hypotheses are and highlight the importance 
of the immune system and inflammation in the aging process. 
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1.5.3 Neuroendocrine Theory 
As the master regulator of the body, the brain is intrinsically linked to 
many of the systems that are suggested to be involved in aging.  The neural and 
endocrine systems together are responsible for communicating and responding to 
the external environment by regulating internal responses to keep the body in an 
optimal functional state for reproduction and survival (157).  Through these 
regulations, the neuroendocrine system is responsible for controlling 
evolutionarily important systems such as reproduction, growth and development 
as well as regulation of stress adaptation (157).   
Many early hypotheses regarding the neuroendocrine involvement in 
aging focused on the role of biological clocks in controlling stages of life.   The 
‘aging clock’ was purported to be located in the hypothalamus, pineal gland, or 
thymus where it regulated the aging process through modification of hormone 
signaling (158-162).  Other groups suggested that there is a defect of the 
hypothalamic pituitary axis, which controls stress responses throughout life.  
Many studies have shown that the hypothalamus is non-uniformly less sensitive 
with increased age and that metabolism and concentrations of neurotransmitters 
are changed as well (163-171).  These alterations lead to secondary changes in the 
peripheral endocrine system creating the disruption of homeostasis that is 
thought to be the cause of aging (171-174). Many studies have focused on the 
decline in growth hormone secretion by the pituitary and associated levels of 
IGF-1 (175).    
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Despite the evidence suggesting a role of the neuroendocrine system in 
aging, attempts to treat individuals with hormone replacement therapy have met 
with controversial results.  Many of the treatments seem successful, but are often 
fraught with side effects. This is true for dehydroepiandrosterone treatment (176-
179) which has beneficial effects on body composition and muscle strength, but 
can lead to declines in the levels of some thyroid globulins and insulin resistance 
(176). Studies of the treatment of growth hormone deficient elderly patients with 
recombinant growth hormone showed positive changes in many features 
associated with aging and popularized the idea of using recombinant growth 
horomone therapy in healthy aging individuals (175,180).  Unfortunately, follow 
up studies on the first group of treated individuals as well as others has shown 
that treatment with recombinant human growth hormone can lead to multiple 
serious side effects (181).  Melatonin has been shown to successfully slow aging in 
mice, but increases tumor growth simultaneously (182,183).  Estrogen 
replacement therapy has multiple beneficial effects (184-186), especially for 
postmenopausal women, but can also increase risk of breast and ovarian cancer 
as well as heart disease (187-189).  Overall, this suggests that targeting the 
neuroendocrine system through hormone replacement therapy is potentially 
beneficial, but side effects occur due to the complex nature of the endocrine 
system. 
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1.5.4 Neuroendocrine-Immuno Theory 
 The neuroendocrine and immune system are tightly linked due to their 
overlap in function.  These systems have shared components, most notably the 
shared use of ligands and receptors of “classical” hormones and 
immunoregulatory mediators (190).  These shared components allow for 
bidirectional communication between the two systems (191-193).  Through this 
communication, cytokines from the immune system can regulate the secretory 
phenotype of the hypothalamus pituitary adrenal axis (HPA) (191,192).  This 
results in a cytokine-induced increase in glucocorticoids, which then feeds back 
to the immune system to down-regulate expression and stability of the cytokines 
(194,195).  This feedback loop creates a homeostatic mechanism that can regulate 
both systems to modulate the inflammatory and stress responses (196). 
Since both the neuroendocrine system and the immune system are 
independently implicated in aging, it is not a far stretch to see that the 
interactions between the two systems may be important in regulating the aging 
process.  This theory suggests that it is the disruption of the normal 
communications between the two systems that leads to the altered function.  This 
theory highlights the importance of finding a theory that can unify the multiple 
complex systems that play a role in the aging process. 
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1.6 Conclusions 
As discussed above, there are a multitude of theories on aging that have 
been presented over the past century. Many of them provide insight into possible 
mechanisms of aging, but it is only after looking at them together that a clearer 
picture of what may cause aging emerges. When taken together, it is possible to 
see how many of the theories are intertwined emphasizing different pieces of the 
complex aging puzzle that focus on different levels of complexity from the cellular 
to whole body systems (Figure 1).   
Despite the major inroads that have been made towards understanding the 
process of aging, it is clear that there is much left to discover.  Efforts to 
understand the aging process will help lead to a population undergoing 
“successful aging” in which not only is disease avoided, but mental and physical 
capacities are maintained and sustained engagement with life is possible (197).  
This goal cannot be achieved purely by analysis of diseases related to aging. It 
requires a deeper understanding of the processes that happen within the aging 
organism. 
 
2. KLOTHO AND AGING  
2.1 Discovery of Klotho 
The serendipitous discovery of klotho (KL) occurred in 1997 during efforts 
to overexpress a sodium-proton exchanger in mice.  In the attempts to make a 
transgenic mouse, approximately 10 copies of the sodium-proton exchanger were 
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inserted in tandem into a single locus of chromosome 5 resulting in disruption of 
the KL promoter (198).  The disruption of the KL gene resulted in a mouse 
displaying a variety of aging phenotypes that were characterized and discussed in 
the seminal paper on KL.  This mouse sparked a lot of interest due to its close 
approximation of normal aging.  In the 16 years since its discovery, much has 
been discovered about the many functions of KL that might help us understand 
the aging process. 
 
2.2 Characterization of Klotho 
2.2.1 Structure of Klotho 
The KL gene consists of 5 exons spanning over 50 kilobases on 
chromosome 13q12 (198-200). From this transcript there are two alternative 
RNA splice variants encoding a membrane and secreted form of KL, which 
consists of exons 1-3 (199).  Despite higher mRNA expression of the secreted 
isoform of KL in humans (199), this splice variant has been identified as a 
candidate for nonsense mediated decay (201).  The full length KL gene encodes a 
a single pass type I transmembrane protein of 1014 amino acids (198).  It consists 
of a small (10 amino acids) intracellular domain of unknown function and a large 
extracellular domain with two internal repeats (Figure 2).   
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Figure 1.  Interconnection of Aging Theories. A diagram of the different 
aging theories presented in a top to bottom hierarchy of system complexity. This 
demonstrates how interconnected the different theories are and how disruption 
of one pathway can lead to the damage of another suggesting the theories should 
not be taken as contrasting ideas, but as part of the same puzzle viewed from 
another angle. 
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The two domains of the extracellular portion of KL (KL1 and KL2) have about a 
21% similarity in amino acids and share homology with family I glycosidases 
including β-glucosidases of bacteria and plants(202) as well as mammalian 
lactase phlorizin-hydrolase (198,203,204).   
 
2.2.2 Expression of Klotho Protein 
KL levels are most highly expressed in the distal convoluted tubules of the 
kidney and choroid plexus of the brain (198).  Kuro-o and colleagues also found 
lower levels of KL mRNA in the pituitary gland, placenta, skeletal muscle, urinary 
bladder, aorta, pancreas, testis, ovary, colon and thyroid gland (198).  These 
results spurred further research from other groups expanding upon these 
preliminary findings.  These studies examined the location of KL in more detail 
finding that KL location in the choroid plexus was mainly isolated to the apical 
surface of ependymal cells. They also showed that localization in the sex organs 
was restricted to the inner regions of the seminiferous tubules of the testis as well  
as the oocytes of Graafian follicles in the ovaries, which are both the most mature 
forms of germ cells in their respective organs (205).  Further investigation of KL 
localization in the brain showed staining not only in the choroid plexus but also 
in Purkinje cells of the cerebellum with a previously unreported perinuclear 
localization in both cell types (206).  KL is also expressed in the parathyroid 
gland of rats (207) as well as in the stria vascularis and spiral ligament of the 
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Figure 2. Schematic representation of KL.  The KL protein is generated 
from 5 exons that make up the full length protein.  It is a type I transmembrane 
protein with a short intracellular region.  Shown are the relative locations of the 
known domains (KL1 and KL2) as well as known cleavage site of ADAM 10/17 
(arrow).  The signal sequence is depicted as a dark gray portion of KL preceding 
exon 1. Magnification of exon 2 depicts the approximate location of the six single 
nucleotide polymorphisms (SNP) that encode for the KLVS variant, including 3 
SNPs located in the intron surrounding exon 2, two SNPs encoding for amino 
acid changes at phenylalanine 352 and cysteine 370 (in bold letters), and one 
SNP in exon 2 that does not change the amino acid sequence. 
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inner ear of mice (208).  In human cell lines and tissues, KL expression has been 
found in breast tissue (209), thoracic aorta (210) and human colorectal cancer 
cell lines (211).  KL is expressed in a variety of tissues, but many of the organs 
that are affected by lack of KL do not express it at high levels.  This suggests that 
shed KL is necessary for its age-associated effects and functions as a circulating 
hormone. 
 
2.2.3 Klotho Gene Regulation 
Early on, the putative KL promoter was identified and found to be heavily 
GC rich (199).  This lends it to regulation by methylation, which can determine its 
tissue specificity (212).  The GC rich region has also been associated with 
alterations in KL expression with age (213) as well as with diseases such as cancer 
and chronic kidney disease (211,214-219).  The KL promoter also has binding 
sites for transcription factors such as specificity protein 1 (Sp1) (199) and early 
growth response protein 1 (Egr1) (220), which can regulate its expression.  
External factors such as oxidative stress (221), inflammation via nuclear factor 
kappa-light-chain-enhancer of activated B cells (NFκB) (222), and dehydration 
through increased antidiuretic hormone and aldosterone (223) can all lead to 
decreases in KL expression.  Conversely studies have shown that Gentian root, 
statins and other compounds are capable of increasing KL promoter activity 
(224-226) and that sirtuin 1 (SIRT1) and vitamin D can increase KL mRNA levels 
(227,228). Recent studies have also identified microRNAs that are capable of 
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decreasing KL levels in vitro (229).  Research in KL gene regulation still has 
many stones to upturn.  Although these are promising results, there is still not a 
full picture of how KL is regulated. 
 
2.2.4 Klotho Protein Processing 
Klotho, like many transmembrane proteins, trafficks through the 
endoplasmic reticulum and golgi to reach the plasma membrane and in this 
process it is glycosylated (230).  Once it is at the membrane, it can be cleaved by 
A Disintegrin and Metalloproteinase (ADAM) 10 and 17 or β-secretase to release 
the KL1 and KL2 domains into the extracellular space (231,232).  This cleavage is 
modulated by insulin and IGF-1 signaling (231).  The leftover membrane-bound 
portion is also a substrate for γ-secretase, which may aid in the removal of the 
remaining C-terminal fragment from the membrane (232). The released 
extracellular domain can be found in the blood and cerebrospinal fluid (CSF) of 
humans and mice.  It was shown by size exclusion gel filtration that this shed 
portion is often found in dimers or higher order oligomers (230).  Further co-
immunoprecipitation as well as metabolic labeling experiments supported this 
finding showing that KL molecules associated with each other within the cell 
(230,231).  Due to the nature of KL, understanding how it is processed and 
trafficked to the membrane is important. Processing at the membrane is fairly 
well understood, but the events preceding and proceeding it are still being 
discovered.  
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2.3 Klotho Deficient Mouse 
2.3.1 General Properties  
 Before 3 to 4 weeks of age, KL mice are indistinguishable from their wild 
type littermates, but around this time growth retardation starts to become 
apparent (198).  Except for the aforementioned smaller body size and display of 
kyphosis, the gross appearance of the KL mice is relatively normal (198).  After 
the onset of growth retardation at 3 to 4 weeks, the knockout mice gain almost no 
weight and slowly become lethargic and malnourished until their death at around 
8-9 weeks of age (198).  Unfortunately, the exact cause of death could not be 
determined because the multitude of disorders present in the mice were not fatal 
within themselves (198). 
 
2.3.2 Hypogonadism 
KL deficient mice never reach sexual maturity and are infertile likely due 
to their atrophic internal and external genitalia.  The atrophic testes do not 
contain any mature sperm as the maturation of spermatocytes is halted at the 
pachytene stage (198).  Observations that levels of dynamin 2 and 3 are reduced 
in the testes of KL deficient mice suggest that alterations in endocytosis may 
explain the decreased spermatogenesis in these animals (233).  The ovaries are 
also atrophied containing primary and secondary follicles, but not Graafian 
follicles or corpus lutea (198).  The ovarian atrophy is likely due to defects in 
hypothalamus and pituitary function.  Not only are levels of lutenizing hormone 
 27 
and follicle stimulating hormones low in KL deficient mice, but normal ovarian 
maturation can be restored by gonadotrophin treatment.  Ovaries from KL 
deficient mice can also function normally when transplanted into a wildtype 
female suggesting the atrophy is due to alterations in circulating hormones (234).   
 
2.3.3 Premature Thymic involution 
The thymus of KL deficient mice develops normally until 3 to 4 weeks of 
age at which point it starts to atrophy, becoming almost undetectable by death at 
6-9 weeks (198).  Hematopoietic stem cells from KL deficient mice are capable of 
differentiating into normal lymphoid cells if transplanted into severe combined 
immunodeficiency (SCID) mice suggesting that there is no intrinsic defect in the 
lymphohematopoietic progenitors (235).  It is thought the atrophy may be caused 
in a similar manner to normal aging (236) in which there is a defect in the thymic 
endothelial cells that are necessary for support and proliferation of thymocytes 
(237-240).  This is supported by the fact that injection of keratinocyte growth 
factor induces proliferation of thymic endothelial cells and is capable of 
improving thymopoiesis and restoring thymic degeneration in both KL deficient 
mice and aged wild-type mice (235).  Taken together, evidence suggests that 
thymic involution in the KL mouse resembles the thymic phenotype seen in 
normal aging supporting the use of KL deficient mice as an accelerated aging 
model. 
  
 28 
2.3.4 Tissue Calcification 
Ectopic calcification presents in KL deficient mice around 4 weeks and 
progresses with age (198).  It can be seen in many soft tissues most notably in the 
gastric mucosa, trachea, renal tubules, small arteries of the kidney, middle-sized 
muscular arteries, and larger renal and aortic arteries (198).  The vascular 
calcification present does not result in intimal thickening or accumulation of 
foam cells associated with typical disease associated arteriosclerosis (198).  
Instead, the vascular calcification more resembles Mönckeberg-type 
arteriosclerosis, which is observed in aged individuals as well as patients 
suffering from diabetes or chronic kidney disease (198).  Further studies 
suggested that the calcification may be secondary to changes in calcium, 
phosphate and vitamin D levels (241,242).   
 
2.3.5 Impaired Bone Mineralization 
KL deficiency in mice results in osteopenia with cortical bone thickness of 
the tibia, femur and vertebrae decreasing between 20 and 40% (198,243).  The 
mice have significant reductions in both bone formation and resorption, but the 
reductions in formation are greater resulting in a net bone loss with low turnover 
(198).  This pathology is similar to estrogen independent osteoporosis seen in 
aging individuals (244).  Despite the cortical bone loss, there is an increase in 
trabecular bone mass in the vertebrae and the metaphysis of tibia and femur of 
KL deficient mice (243,245,246).   
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2.3.6 Skin Atrophy 
KL deficient mice had more sparse hair than wild-type mice (198).  
Further histological examination showed that there is a reduction in the number 
of hair follicles(198), similar to what is found in old age (247).  Other features 
common in old age were also found in the mice such as decreases in dermal and 
epidermal thickness as well as almost undetectable levels of subcutaneous fat 
(198).   
 
2.3.7 Pulmonary Emphysema 
At around 5 weeks of age, KL deficient mice start to develop enlarged air 
spaces distal to the terminal bronchiole and destruction of alveolar walls (198).  
This is concomitant with an increase in levels and activity of matrix 
metalloproteinase 9 (MMP-9) and decreased levels of tissue inhibitor of matrix 
metalloproteinase-1 (TIMP-1) in the lung, suggesting the imbalance of these 
enzymes may be contributing to the onset of emphysema (248). There is also an 
increase in the amount of apoptotic cells accompanied by a decrease in lung 
elastic recoil (249).  At later stages, calcium deposits in type I collagen fibers of 
alveolar septa are present and type II pneumocytes start to degenerate (250).  
Functionally, the mice had longer expiration times and higher dynamic 
compliance than wild-type mice, which is similar to patients with emphysema 
(250).  A computational study comparing the pulmonary damage seen in KL 
deficient mice to damage from smoking-related emphysema concluded that the 
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KL mouse phenotype more closely resembled systemic damage due to old age 
rather than local damage caused by smoking or other artificial means (251).   
     
2.3.8 Neural Deficits  
Kuro-o and colleagues first reported changes in the neural function of KL 
deficient mice in the seminal paper that described the KL phenotype (198). They 
found the mice have a parkinsonian-like gait that is accompanied by loss and 
degeneration of Purkinje cells (198).  There is also loss of mesencephalic 
dopaminergic cells in the substantia nigra and ventral tegmental area, which is 
also associated with Parkinson’s disease.  Further studies showed that KL 
deficient mice have decreased cognitive capacities as assessed by novel-object 
recognition and fear conditioning tests (252).  Changes in DNA and lipid 
peroxide levels as well as increases in apoptotic markers in the hippocampus 
suggest that increases in oxidative stress may be the cause of the cognitive deficits 
(252).  Other researchers also found evidence of neurodegeneration in cellular 
organelles of hippocampal cells (253).  The importance of oxidative stress is 
supported by data showing administration of α-Tocopherol, an antioxidant, 
prevented the cognitive deficits while simultaneously lowering the oxidative 
stress levels and number of apoptotic cells (252).  KL deficient mice also have 
decreased amounts of anterior horn cells in the spinal cord, which is seen in 
amyotrophic lateral sclerosis (254).  These neurons have decreased levels of 
ribosomal RNA gene transcription and a concomitant reduction in cytoplasmic 
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RNA and rough endoplasmic reticulum (RER) (254).  This study, along with 
others, also showed increases in the amount of glial fibrillary acidic protein 
(GFAP)(253,254), which is associated with increased age of an organism (255-
257).  An exhaustive immunohistochemical analysis of the brains of KL knockout 
mice expanded upon previous findings showing that lack of KL increases levels 
and phosphorylation of neurofilaments, decreases microtubule-associated 
protein 2 (MAP2) expression and increases lysosomes and autophagy related 
structures and markers (253). These changes seen with KL mice are all 
independently associated with normal aging.  Neurofilament levels are increased 
in aging animals and in age-related neurodegenerative diseases (258-264).  
Levels of neurofilament phosphorylation, which have also been reported to 
change in KL mice by two other groups (254,265), are enhanced in 
neurodegenerative and/or aging conditions (258,259).  Studies by Chen and 
colleagues show that neurons are not the only brain derived cell to be affected by 
KL deficiency.  Myelination is also altered in the optic nerve and corpus callosum 
of these mice due to decreased levels of mature oligodendrocytes showing that KL 
is also important for proper oligodendrocyte maturation and myelination (266).  
Overall, KL has a variety of functions on the nervous system most likely due to its 
humoral effects that allow it to have far-reaching targets. 
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2.3.9 Hearing Loss 
Klotho expression in the ear is localized to the stria vascularis and spiral 
ligament of the inner ear(208). In KL deficient mice, there are no obvious 
morphological abnormalities of the ear, but the threshold for the auditory 
brainstem response was significantly higher and wave I latencies were prolonged 
(208).  This difference may be regulated by KL’s effect on ion homeostasis 
through which it could modulate endolymph fluid levels.  This is supported by 
changes in the levels of ion channels regulated by KL in the inner ear with age 
(267). 
 
2.3.10 Cardiovascular Deficits 
KL expression in the heart is limited to the sinoatrial node, which acts as 
the pacemaker for the rest of the circulatory system (268).  Investigation into the 
effect of KL deficiency on the heart showed that KL deficient mice had higher 
rates of sudden death after long periods of restraint stress (268).  This difference 
is due to an abnormal stress response that led to a longer recovery time in the KL 
deficient mice leading to sudden death (268).  Further investigation of the 
cardiovascular system of KL deficient mice showed that they also suffer from 
impaired angiogenesis and vasculogenesis (269).  These changes may be due to 
KL’s regulation of nitric oxide synthesis.   
 
 
 33 
2.3.11 Blood Chemistry 
Alterations in the blood chemistry of KL deficient mice consist of 
increased levels of serum phosphorus, calcium and active vitamin D (241) and 
decreased levels of glucose (270). Further studies showed that despite decreases 
in glucose, insulin levels were also decreased (270).  These seemingly conflicting 
results are due to increased insulin sensitivity in the KL deficient mice (270).  The 
ratio of lymphocytes to leukocytes was also decreased probably due to thymic 
involution (198).  Other measurements such as creatinine, total protein, albumin, 
cholesterol and triglyceride levels were unchanged (198).  The changes in blood 
chemistry seen in KL deficient mice are present before the onset of symptoms, 
suggesting that they are important in the age-related effects of these mice.  
 
2.3.12 Rescue of Phenotypes by Klotho Expression 
Thirty-seven transgenic mouse lines were developed under the control of 
the EF-1α promoter in order to test whether exogenous expression of KL in the 
KL deficient mice could rescue the aging phenotypes (198).  Two of these lines 
have detectable levels of KL measured by RNAse protection assays and are able to 
rescue most of the phenotypes.  The rescued mice have an appearance almost 
indistinguishable from wild type and also have close to normal thymus and 
genital organ sizes and composition, which resulted in fertile mice.  Blood 
chemistry values are near normal and calcification, including atherosclerosis, is 
markedly decreased.  Cortical bone thickness is normal and osteopenia is 
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improved. Other measurements taken, such as emphysema and skin changes, are 
ameliorated.  Overall, rescue of KL expression markedly improves the aging 
phenotype of the klotho deficient mice.  Interestingly, only one of the lines 
resulted in KL overexpression in all tissues examined (kidney, brain, lung, 
ovaries, testes etc.).  The other transgene that is able to rescue could only be 
found in the brain and testes.  This suggests that many of the aging phenotypes 
associated with KL are regulated by these areas or that KL’s ability to act as a 
humoral factor is crucial for its effect on aging.  The ability of parabiosis of wild-
type mice with KL deficient mice to restore endothelial function suggests that it is 
KL’s humoral function that is responsible for the wide-ranging effects (271).  
Another independently created model of KL rescue relied on zinc dependent 
induction of KL in KL deficient mice (272).  This showed that KL expression was 
able to rescue the age-related phenotypes of KL deficient mice even after the 
onset of symptoms.  Turning off KL gene expression led to a resurgence of the 
symptoms further illustrating that changes in KL levels are responsible and 
sufficient to modify the aging phenotype of the mice.  This suggests that 
increasing KL levels in aging individuals could be enough to slow or reverse the 
phenotypes present.   
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2.4 Klotho Overexpressing Mouse 
2.4.1 Phenotype of KL overexpression 
The two transgenic mouse lines that were first made to rescue the KL 
deficient phenotype were further studied to look at their effects independent of 
KL deficiency (273).  Both lines led to increases in lifespan of 20-30% in males 
and approximately 19% in females.  This increase in lifespan could not be 
explained by decreased caloric intake or body size, but the overexpressing mice 
did have smaller litters than wild-type controls.  Despite normal caloric intake, 
these mice have a similar increase in lifespan as is seen by inhibition of the 
insulin/IGF pathway.  These mice had normal blood glucose levels, but higher 
circulating insulin levels.  This was explained by the fact that the transgenic mice 
displayed insulin and IGF-1 resistance, although insulin resistance was not 
shown in female transgenic mice.  The differences in the insulin/IGF pathway 
suggest that KL’s inhibition of insulin/IGF signaling may be important for its 
longevity effects.  This would tie in with the independent studies showing 
associations between inhibition of this pathway and longevity (274).   
 
2.4.2 Protective Effects of KL Overexpression 
Further studies showed that transgenic mice overexpressing KL had 
decreased levels of oxidative stress as measured by 8-Hydroxydeoxyguanosine 
(8-OHdG) urinary excretion and were protected from a lethal dose of the 
herbicide paraquat that generates reactive oxygen species (275).  Both of these 
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results suggest that KL overexpression protects against oxidative stress.  KL 
overexpression was also protective in models of renal and cardiovascular damage 
as well as in a multiple risk factor syndrome (276-279).  Another group examined 
KL expression in 20 different inbred mouse strains and discovered that one of the 
strains had high expression levels of KL mRNA.  This strain had better hearing 
and reduced risk of arteriosclerosis compared to the other strains with less KL 
expression (280).  This shows that higher levels of KL expression, even when not 
artificially induced, are protective against age-related phenotypes.  KL’s relation 
to decreased oxidative damage ties back to the free radical theory of aging, giving 
credence to both the theory and KL’s anti-aging effects, suggesting they may be 
linked to its ability to control oxidative stress.   
 
2.5 Klotho Functions 
KL deficiency results in a global phenotype that affects a wide range of 
tissue types culminating in decreased longevity.  Due to shed KL’s humoral 
activity, it is possible for KL to have many functions on a variety of tissue types.  
Although it is still unclear what functions of KL are direct and which may be 
secondary effects of a different function, KL has been implicated to regulate many 
pathways through which it can have its wide-ranging age related effects. 
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2.5.1 Klotho and Fibroblast Growth Factor Signaling 
The first function of KL was discovered when it was realized that the 
phenotype of fibroblast growth factor 23 (FGF23) knockout mice heavily 
overlapped with mice deficient in KL (198,281).  Beside the predicted phenotypes 
of hyperphosphatemia and soft tissue calcification, the mice also demonstrated a 
shortened lifespan, growth retardation, hypogonadism, premature thymic 
involution, osteopenia, sacropenia, skin atrophy and pulmonary emphysema 
which are all reminiscent of the KL deficient mice (198,281-283).  Supporting the 
role of KL in FGF23 signaling, the double knockout of KL and FGF23 has 
identical phenotypes to their single knockout counterparts.  Injection of FGF23 
could not rescue the phenotypes as it does for FGF23 knockout mice alone (284) 
implicating KL in FGF23 signaling.  KL mice also had very high serum levels of 
FGF23 suggesting that KL deficiency results in severe FGF23 insensitivity (285) 
further supporting the role of KL in FGF23 signaling.  In fact, FGF23 and two 
other fibroblast growth factors (FGF), FGF19 and 21, were found to be atypical 
members of the FGF superfamily (286,287).  Unlike the canonical FGFs that have 
autocrine or paracrine actions, these members of the family act as endocrine 
factors because of the low heparin binding affinity attributed to their unique 
structure (288,289).  This unique structure allows them to travel past the heparin 
sulfate rich extracellular matrix to have more endocrine like effects, but the 
affinity of FGFs for heparin sulfate is critical for their binding to Fibroblast 
Growth Factor Receptors (FGFR) (290).  To this end, FGF23 is not capable of 
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activating cultured cells even when there is endogenous expression of FGFRs 
(291) suggesting that it requires a cofactor for proper activity.  It was shown that 
KL was capable of binding FGFR and acting as the obligate co-receptor for FGF23 
binding and signaling (285,291).  Through this signaling, the complex activates 
Fibroblast Growth Factor Receptor Substrate 2α (FRS2α) leading to downstream 
extracellular signal-related kinase (ERK) 1/2 phosphorylation and eventually 
leading to increased expression Egr1 mRNA, suggesting the signaling leads to 
transcriptional regulation of this transcription factor (285,291).   
In the kidney, FGF23 released from bone and KL promote phosphate 
excretion into urine by down-regulating the amount of sodium-phosphate co-
transporter type 2a (NaPi-2a) present on the apical brush border membrane of 
proximal tubules (292-296).  They also regulate levels of 1,25(OH)2D, the active 
form of vitamin D, by inhibiting the activity of 1-α-hydroxylase (292,297,298).  
Reduction of vitamin D synthesis also leads to decreased phosphate absorption in 
the intestine further promoting decreased plasma phosphate levels (299).  The 
active form of vitamin D completes the negative feedback loop between FGF23, 
KL and itself by independently up-regulating the FGF23 and KL genes (Figure 3) 
(227,298) 
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Figure 3. Klotho Control of FGF23 Signaling.  Regulation of vitamin D 
metabosim is maintained by klotho and FGF23 signaling. In the bone, active 
vitamin D binds to the vitamin D receptor (VDR), which makes a complex with 
the nuclear receptor RXR. The formed complex binds to a region of the FGF23 
promoter leading to increased expression of FGF23.  FGF23 secreted from the 
bone acts on the klotho-FGFR complex in the kidney and the parathyroid gland.  
In the kidney, downstream signaling of FGF23 suppresses expression of Cyp27b1 
gene that encodes 1α-hydroxylase and closes a negative feedback loop for vitamin 
D homeostasis. In the parathyroid gland, FGF23 signaling suppresses expression 
of PTH. Since PTH is a potent inducer of Cyp27b1 gene expression, suppression 
of PTH by FGF23 reduces expression of Cyp27b1 gene as well as serum levels of 
1,25-dihydroxyvitamin D3, which closes another negative feedback loop for 
vitamin D homeostasis. Klotho and FGF23 are indispensable for the regulation of 
vitamin D metabolism, because defects in either Klotho or FGF23 cause 
hypervitaminosis D. Diagram from Kuro-0, 2009 .  
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FGF23 and KL also act in the parathyroid gland to regulate phosphate 
homeostasis as well as calcium metabolism.  FGF23/KL signaling can down-
regulate parathyroid hormone (PTH)(207,300), which much like the FGF23/KL 
complex leads to phosphaturia (301,302), but increases serum levels of active  
vitamin D (Figure 3) (303).  This modulation of hormones in the endocrine 
system by KL hearkens back to the theories positing a role of the endocrine 
system in aging.  Since the KL and FGF knockout mice show that this function is 
important for the anti-aging effects of KL, it adds strength to the theory that the 
endocrine system plays a crucial role in aging.  
The importance of FGF23 signaling in the aging-related effects of KL is 
highlighted by the similarities of the two knockout mice (273,282,283,295).  The 
importance of this pathway is further illustrated by the ability of a low  
vitamin D diet to rescue the altered serum phosphate and calcium levels in both 
FGF and KL knockout mice preventing the expression of the age related 
phenotypes (241,304).  A similar rescue occurs when the vitamin D receptor gene 
or the cytochrome P450 2B1 (Cyp2b1) gene that helps transcribe 1-α-hydroxylase 
is ablated (305-307) leading to a similar decrease in the amount of active vitamin 
D.  A low phosphate diet is also able to rescue the shortened lifespan and vascular 
calcification in both mice models (304,308).  All of this points to the importance 
of the regulation of phosphate and vitamin D homeostasis by KL and FGF23 
signaling.   
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2.5.2 Klotho Regulation of Ion Channels 
KL knockout mice have altered phosphate and calcium ion levels 
suggesting that KL plays a role in ion homeostasis (198).  One way that KL may 
control ion homeostasis is through its regulation of the membrane localization of 
ion channels.  The shed extracellular domain of KL is capable of modulating 
membrane levels of transient receptor potential vallinoid (TRPV) channels, 
TRPV5 and TRPV6, leading to their increased localization at the membrane 
(309,310).  Both channels are important in regulating calcium levels: TRPV5 is 
mainly located in the distal convoluted tubules and connecting tubules where it 
mediates renal transcellular transport leading to calcium reabsorption while 
TRPV6 mediates calcium absorption in the intestine (311).  Investigation into the 
mechanism of KL induced membrane localization showed that this process was 
mediated by KL’s enzymatic activity, which may be linked to its weak homology 
to β-glycosidases (312).  KL cleaves off an N-terminal sialic acid from the glycan 
chain, which exposes the N-acetyllactosamine (LacNAc) (313).  The exposed 
LacNAC can then bind to galectin-1, which prevents TRPV endocytosis leading to 
increased presence of channels on the plasma membrane (Figure 4) (313).  KL is 
also able to regulate the membrane localization of renal outer medullary 
potassium channel 1 (ROMK1) in a similar manner (314).  In the case of ROMK1, 
increased membrane localization leads to a rise in potassium reabsorption by the 
kidney and more urinary excretion of potassium (314).  The renal phosphate 
transporter NaPi-2a and NaPi 2b are also regulated by KL’s enzymatic activity,  
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Figure 4.  Regulation of Ion Channels by KL-mediated Removal of 
Sialic Acid.  When located at the plasma membrane, ion channels such as 
TRPV5 and ROMK1 undergo regular endocytosis to maintain an equilibrium at 
the membrane. The extracellular domain of KL is capable of regulating the 
membrane localization of such ion channels by manipulating the glycan chain on 
these channels. Klotho cleaves off an N-terminal sialic acid from the glycan chain, 
which exposes the LacNAc.  The exposed LacNAC can then bind to galectin-1, 
which effectively stabilizes the ion channels on the plasma membrane. Diagram 
from Huang CL, 2011 (317). 
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but in this case KL leads to a decrease of cell surface expression instead of the 
increase seen with the other ion channels (315,316).   
KL also regulates the membrane localization of transient-receptor 
potential canonical calcium channel (TRPC) 1 and TRPC6, but the mechanism of 
action is not through KL’s enzymatic activity (276,318).  TRPC1 is involved in 
vascular endothelial growth factor (VEGF) mediated calcium entry and KL is able 
to bind to the complex of TRPC1 and vascular endothelial growth factor receptor 
2 (VEGFR2) to strengthen it and promote the complex internalization upon 
VEGF stimulation (318). Klotho can also interact with TRPC6 through which it 
can down-regulate the receptor.  This action is cardioprotective as excess TRPC6 
levels in mice lead to spontaneous cardiac hypertrophy that is ameliorated by 
soluble KL expression (276).  It is possible that KL regulates TRPC6 by a different 
mechanism than TRPC1 because Kusaba and colleagues could not pull down a 
KL-TRPC6 complex (318).   
 
2.5.3 Klotho Inhibits Insulin/IGF Signaling  
While KL deficient mice present with hypoinsulinemia, hypoglycemia and 
extreme insulin sensitivity (198,270), KL overexpressing mice are insulin/IGF-1 
resistant despite maintaining normal fasting blood glucose levels and not 
developing diabetes (273).  The prevalence of insulin/IGF-1 related symptoms in 
the KL mice models suggest that KL plays a role in regulating insulin/IGF  
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Figure 5.  Klotho Inhibits the Insulin/IGF Pathway. Diagram depicting 
the interactions of KL with the insulin/IGF pathway, which is independently 
implicated in aging. PI3K signaling downstream of IGFR can lead to activation of 
AKT and subsequent phosphorylation and inactivation of FOXOs. When 
activated, FOXO’s can upregulate the expression of genes associated with 
longevity. Through PDK1, PI3K signaling can also activate NFκB, which leads to a 
senescent phenotype.  Klotho can inhibit downstream signaling through the 
insulin/IGF pathway by an unknown mechanism.  Through this inhibition, KL 
can upregulate longevity associated genes and inhibit the senescence phenotype. 
Diagram from Salminen et al., 2010{Salminen, 2010 #852}.  
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signaling.  This is supported by KL’s ability to inhibit insulin signaling in cultured 
cells (209,273).  Although the mechanism by which KL inhibits insulin signaling 
is unclear, it is possible it is through KL’s enzymatic activity.  N-glycosylation of 
insulin receptors can affect its function and localization (319) and sialidase 
expression has been linked to development of insulin resistance in cultured cells 
and mouse models (320,321).  There are findings that suggest the action of KL on 
insulin signaling may not be direct (322), but evidence from C. elegans suggests 
that KL inhibition of insulin/IGF signaling is necessary for its effect on longevity 
(323).   The involvement of insulin/IGF in KL’s longevity effect is supported by 
the fact that insulin/IGF signaling has been independently linked to longevity 
(Figure 5) (81,82,324-328).  The link between these two pathways further 
bolsters the hypothesis that they are involved in the aging process and 
emphasizes the interconnections between different pathways involved in aging. 
 
2.5.4 Klotho Inhibition of Other Growth Factors 
Although more attention is paid to KL’s association with the insulin/IGF 
pathway due to its close ties to aging, KL also regulates the activities of other 
growth factors.  KL also binds to wnt ligands including Wnt1, Wnt3, Wnt4 and 
Wnt5a (329).  This interaction inhibits wnt signaling, which could explain the 
increase in wnt activity seen in klotho deficient mice (329).  Wnt can regulate 
bone mass suggesting that KL regulation of this pathway could explain the 
increased bone mass seen in certain bones of KL deficient mice.  The wnt 
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pathway is also involved in the kidney injury that is associated with loss of KL 
(330) and has been implicated in cancer progression as well as oligodendrocyte 
maturation that KL is known to affect (331-333).  Another growth factor, 
transforming growth factor β (TGFβ), forms a negative feedback loop with KL.  
TGFβ is capable of down-regulating KL expression in the kidney (330,334) and 
KL is capable of binding directly to the type II TGFβ receptors disrupting the 
binding of its ligand and therefore inhibiting downstream signaling (335).  Klotho 
also inhibits VEGF signaling by promoting the internalization of the VEGFR2-
TRPC1 complex (318). There is also a strong negative correlation between levels 
of VEGF and KL in kidney disease (318) and there is also decreased staining for 
VEGF in the aorta of KL heterozygote mice (336) further implicating KL in VEGF 
inhibition.  It is possible that KL plays a major role in regulation of the epithelial 
to mesenchymal transition (EMT) because of its inhibition of the many growth 
factors discussed above that promote it (337,338). Since EMT is associated with 
many diseases, it is possible that KL may regulate disease risk through this 
pathway (339-341).  
 
2.5.5 Klotho and Oxidative Stress  
Evidence from both KL deficient mice and overexpressing mice suggest 
that KL plays a role in oxidative stress.  While deficient mice show increased 
levels of DNA and lipid oxidative stress in the hippocampus (252), overexpressing 
mice showed low levels of oxidative stress accompanied by increased levels of 
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superoxide dismutase and resistance to lethal levels of oxidative damage (275). 
KL’s regulation of oxidative stress could be through its inhibition of insulin/IGF 
signaling.  This pathway negatively regulates FOXO transcription factors by 
leading to their phosphorylation and degradation (342).  When activated, FOXOs 
lead to upregulation of antioxidant proteins including mitochondrial manganese 
superoxide dismutase (SOD2) (343).  This protein is also upregulated in muscles 
by KL overexpression potentially through KL’s dis-inhibition of FOXOs (275).  
Expression of KL is also regulated by SIRT1 (228), another gene that has been 
independently associated with protection from oxidative stress (344) further 
supporting KL’s involvement in oxidative stress.  The involvement of both FOXOs 
and SIRT1 suggest that KL’s ability to protect against oxidative stress may be 
related to its inhibition of insulin/IGF signaling as these molecules are known to 
be inhibited by insulin/IGF signaling.  
 
2.5.6 Klotho’s Anti-Inflammatory/Immune System Function 
KL’s role in the immune system was first suggested when it was found that 
KL deficiency can lead to premature thymic involution (198).  KL deficient mice 
also have higher rates of sepsis-induced T-lymphocyte apoptosis as well as higher 
levels of cytokines (345).  KL is also downregulated in cluster of differentiation 4 
(CD4) positive T-lymphocytes of healthy elderly individuals and this 
downregulation is even stronger in individuals with rheumatoid arthritis (346).  
KL may also have an indirect effect on B-lymphocytes as evidenced by the early 
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impaired B cell development in bone marrow of KL deficient mice (347).  KL not 
only regulates lymphocyte development and response, but it also regulates tissue 
response to released cytokines (348).  Pre-incubation with KL inhibits the effects 
of TNF-α in human umbilical vein endothelial cells resulting in a decreased 
induction of adhesion molecules as well as reduced levels of NF-κB (348).  
Further investigation revealed this mechanism is dependent on phosphorylation 
of reticuloendotheliosis oncogene cellular homolog A (Rel A) (349).  KL can also 
protect from senescence-induced inflammation through down-regulation of 
retinoic acid inducible gene-1 (RIG-1) (350).  Together, these studies show KL 
can regulate the immune system in two ways: by regulating expression and 
function of immune cells such as lymphocytes and by regulating tissue response 
to cytokines and other inflammatory signals.  Regulation of the immune system is 
postited to play a role in the aging process by the Immune Hypothesis and it is 
possible that KL’s regulation of this system is important for its age-related effects.  
  
2.5.7 Klotho and Senescence 
KL’s links to protection from oxidative stress and inhibition of 
inflammation make it a strong candidate for regulation of senescence.  The 
overlap of these conditions can be seen by KL’s aforementioned ability to inhibit 
senescence-associated inflammation (350).  KL is able to protect from oxidative 
stress induced senescence (351,352), cytokine induced senescence and replicative 
senescence (353).  KL can also protect against stress-induced telomere 
 49 
shortening (353), which often leads to senescence.  Levels of senescence also 
increase in epidermal cells of KL deficient mice (329).  Downregulation of KL can 
lead an increase in senescence as demonstrated by expression of KL RNA 
interference (RNAi) or by administration of KL lowering compounds (354,355).  
Multiple studies show that KL inhibition of senescence is through a mitogen 
activated protein kinase (MAPK)/ERK dependent down-regulation of p53 and 
protein 21 (p21) (351,352,354).  Senescence is often used as a marker for aging so 
KL’s regulation of this event, which is linked to its ability to regulate oxidative 
stress and inflammation, may play a role in its age related functions.     
 
2.5.8 Klotho and Nitric Oxide Synthesis 
KL deficient mice have impaired acetylcholine-induced endothelium-
dependent vasodilation of aorta and arterioles (271).  This finding suggested that 
KL plays a role in nitric oxide (NO) synthesis because of the importance of NO in 
vascular tone.  Further studies showed responses to norepinephrine and 
superoxide dismutase were also altered in these mice (336).  Angiogenesis and 
vasculogenesis, which are also reliant on NO signaling, are impaired in KL 
deficient mice (269).  This decrease in NO synthesis of KL deficient mice is 
systemic as evidenced by the decrease in urinary excretion of NO metabolites 
(271).  Gene delivery of KL is able to rescue endothelial dysfunction through 
increased NO synthesis in a mouse model of multiple atherogenic risk factors 
(278).  Evidence from heterozygous KL deficient mice also suggests that  
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Figure 6.  Klotho’s Activity in Ion Homeostasis and Beyond.  KL can 
function through various pathways in an autocrine, endocrine or paracrine 
fashion.  It can regulate downstream Ca2+/PO4 3– homeostasis by negatively 
regulating 1,25(OH)2D3 synthesis, and adjusting PO4 3– directly, bypassing the 
vitamin D pathway.  Klotho can also indirectly affect the vitamin D- Ca2+/PO4 
circuit through other mediators including PTH and TRPV5.  Many other 
pathways regulated by KL may also influence the vitamin D- Ca2+/PO4 circuit 
through unknown mechanisms, but together it is known that the pathways KL 
regulates lead to increased longevity when activated. Diagram from Wong F, and 
Q. Xu, 2009 (356). 
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differences in NO synthesis are not due to alterations in phosphate or vitamin D 
homeostasis because changes in ion homeostasis are not present in these mice.  
The amelioration of symptoms through parabiosis with a wildtype mouse also 
suggests that the alterations in NO synthesis are due to the humoral effects of the 
shed form of KL (271).   
 
2.5.9 Summary 
KL is able to regulate many age-related pathways resulting in a protein 
that is heavily implicated in the aging process.  It is still unclear whether KL 
directly regulates all of these pathways or whether a few functions of KL mediate 
secondary effects creating a large web of functional changes associated with 
altering levels of KL. So far, KL’s regulation of FGF and other growth factors is 
highly implicated as a primary effect of KL necessary for its aging phenotype. 
Through FGF signaling and other means, KL can regulate ion and vitamin D 
homeostasis, which seems to be another key function of KL.  KL acts through 
these mechanisms to decrease levels of oxidative stress, prevent premature 
senescence and lead to a protein that can increase longevity (Figure 6).  
 
2.6 Klotho and Disease 
KL’s association with multiple processes of aging indicate that it may 
regulate risk factors previously implicated in age-related disorders.  Evidence 
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from the KL deficient mice further suggest KL is a regulator of age-related 
diseases. Implications from model organisms as well as recent advances in 
measuring KL levels in serum have led to an increase in the amount of research 
studying KL levels in human diseases.  These studies, which are described below, 
show that KL is altered in many diseases.  It is possible, as suggested by KL 
studies in model organisms, that these changes in KL could play a direct role in 
the pathology of the discussed diseases.  Investigations of KL’s role in human 
disease can help elucidate what function KL is playing in human physiology.  
 
2.6.1 Chronic Kidney Disease  
The high levels of KL found in mice kidney suggests that it has an 
important function in this organ.  This is further substantiated by the results of 
studies that show angiotensin II induces down-regulation of KL (357).  Inhibition 
of angiotensin II and the related renin-angiotensin-aldosterone system (RAAS) is 
a major target of chronic kidney disease (CKD) therapy (358) and can lead to 
increases in KL levels (359).  This suggests that KL down-regulation may lead to 
some of the symptoms seen in CKD.  Studies in mouse models of kidney injury 
show that levels of KL can affect the disease outcome. While higher levels of KL 
can protect against acute kidney injury (AKI) and ischemia reperfusion injury 
(IRI), lower KL levels worsen the outcome (360-362).  This action as a 
renoprotective agent suggests that decreases in KL could lead to kidney disease.  
Several articles report that KL levels in the kidney are decreased in many mouse 
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models of kidney disease (278,279,363) as well as human cases of chronic kidney 
disease (364,365).  Measurements of KL in the urine of CKD patients also show 
decreases that start in the early stages of CKD and are positively correlated with 
the severity of disease (361,366).  In mouse models of CKD, increased KL levels 
can be protective, suggesting that targeting KL may be able to alter disease 
outcome in humans (277,279,315,367).   These experiments as well as KL’s ability 
to protect against damage even after the insult in IRI suggests it could be used as 
a therapeutic and that it is more than just a biomarker (360).  
Evidence from mouse models and human patients make it clear that KL is 
involved in CKD, but does not explain what functions of KL are necessary for its 
renoprotection.  Further studies suggested that it is KL’s ability to regulate the 
FGF23-vitamin D axis that affects kidney function.  Through this regulation, it 
can maintain phosphate homeostasis and prevent hyperphosphatemia, which is 
associated with accelerated CKD complications and higher mortality rates (368-
371).  Downregulation of KL can lead to decreased FGF23 sensitivity leading to 
higher levels of circulating FGF23, causing further hyperphosphatemia (372) and 
more severe disease progression (373).  KL’s role in CKD disease progression 
most likely comes from its control of phosphate homeostasis that is dysregulated 
by angiotensin II-induced KL downregulation (357).  Gene transfer of KL is also 
capable of protecting against angiotensin II-mediated renal damage (357).  
Overall, KL is highly implicated in the progression of CKD and this association 
may be relevant to the aging phenotype of KL deficient mice (374).  
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2.6.2 Epilepsy 
Temporal lobe epilepsy (TLE) is characterized by excessive neuronal 
excitation, usually caused by excessive release of glutamate leading to calcium 
overload and eventually cell dysfunction and death.  One of the main pathological 
findings in patients that have suffered from TLE is hippocampal sclerosis (HS).  
HS is identified by increased astrocyte numbers associated with the destruction 
of nearby neurons namely, astrogliosis.  Recently, inflammation has been 
suggested to have a crucial role in epileptogenesis (375) and also has ties to 
increases in astrogliosis (376).  In particular tumor necrosis factor-α (TNF-α) has 
been identified as a regulator of neuroinflammation and cell death in epilepsy 
(375,377,378).  KL has been shown to protect the hippocampus against stress-
induced toxicity and can also inhibit TNF-α signaling. These connections 
suggested that KL might play a role in TLE.  Examination of post-mortem tissue 
of TLE patients with HS showed that there was indeed up-regulation of TNF-α in 
the hippocampus and a concomitant decrease in KL levels (379).  It is possible 
that down-regulation of KL may play a role in the pathogenesis of epilepsy due to 
its roles in controlling inflammation or potentially by its regulation of calcium 
homeostasis via control of membrane localization of calcium channels.  
 
2.6.3 Acromegaly 
Acromegaly is a growth disorder most commonly caused by pituitary 
adenomas that result in increased production of growth hormone and subsequent 
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increases in IGF-1 (380).  This slow-moving disorder eventually leads to organ 
overgrowth and physical deformity over the course of decades.  Metabolically, it 
leads to hyperphosphatemia, hypercalcemia, insulin resistance, high levels of 
FGF and vitamin D, and hyperglycemia (381-383).  The incidence of 
cardiovascular, cerebrovascular, metabolic and respiratory comorbidities lead to 
a decreased life expectancy of approximately 10 years (384,385).  Until recently, 
there was no known connection between KL and acromegaly despite the multiple 
connections between KL and the pathways affected in the disease.  Recent studies 
have shown that serum KL levels are high in patients with acromegaly and that 
these levels decline after removal of the tumor (386-388).  Despite rises in serum 
KL levels, staining for KL in the pituitary is not altered suggesting that it is not 
increased expression by the tumor itself and may be secondary to the systemic 
actions of growth hormone or IGF-1 (387).  In fact, IGF-1 is known to increase 
shedding of full length KL (231), which could, in part, lead to the differences in 
KL. Although the importance of KL in the pathogenesis of acromegaly is yet to be 
determined, these studies suggest that it may be a biomarker of disease presence 
and severity, which could aid in the development of better treatment.  
 
2.6.4 Cancer 
Despite the lack of spontaneous tumor growth in KL deficient mice, low 
levels of KL are associated with many different cancer types.  KL has been 
associated with cancers of the breast, ovary, cervix, lung, pancreas, intestine, 
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colon, skin, stomach and kidney (209,211,216-219,335,389-400).  While most 
studies have found lower KL expression associated with increased severity, one 
study found KL levels increased with disease progression and death in epithelial 
ovarian cancer (389).  This seemingly controversial study may be due to an 
unknown alteration in these cells that leads to decreased KL sensitivity. This 
could explain the higher levels of KL as well as insulin that would increase KL 
cleavage as a compensatory mechanism to try to maintain normal KL levels.  All 
other studies have found low levels of KL associated with tumor progression and 
increased cancer cell growth (209,211,216-219,335,390,391,393,395-400).  
Conversely, increased levels of KL are associated with positive outcome after 
surgery in patients with lung cancer (392,394). Many groups have reported the 
reason for decline of KL levels in cancer is because of hypermethylation of the 
promoter.  This has been found in breast, cervical, gastrointestinal and colorectal 
cancer (211,216-219).  This decline in expression blocks KL from having its tumor 
suppressing activity through inhibition of growth factors 
(209,219,335,390,391,396-400).   Although KL’s inhibition of multiple growth 
factors has been implicated in its tumor suppressing activity, the association with 
the insulin/IGF pathway has been the most researched (209,390,397,400).  KL’s 
tumor suppressing activity has also been independently associated with its 
inhibition of the wnt pathway via its inhibition of Filamin A cleavage 
(219,391,396) and TGF-β signaling by inhibiting induction of the mesenchymal 
phenotype (335).  All of these pathways can regulate similar downstream signals, 
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namely phosphoinositide 3-kinase (PI3K)/Akt/glycogen synthase kinase 3β 
(GSK3β)/snail signaling, which is associated with KL’s tumor growth inhibition 
(398,399). Coupled with the fact that KL levels are often associated with the 
severity and invasiveness of the cancer, it is possible that KL mediates the 
epithelial to mesenchymal transition through its regulation of growth factors 
leading to its inhibitory effects on cancer.    
 
2.6.5 Cardiovascular Disease 
The first studies in KL deficient mice noted that these mice presented with 
atherosclerosis as one of the phenotypes (198).  KL also has a role in maintaining 
endothelial wall homeostasis and health of the vasculature through its regulation 
of nitric oxide (271,401,402).  Endothelial dysfunction, which is often correlated 
with decreased bioavailability of NO, is an early step in the development of 
cardiovascular disease (CVD)(403) suggesting that down-regulation of KL may 
result in increased risk for CVD.  Studies in mice and rats support this hypothesis 
showing that KL protects against cardiovascular injuries through a NO dependent 
mechanism (278,348).  KL’s rescue of NO production is also capable of protecting 
human umbilical vein endothelial cells (HUVECs) from expression of adhesion 
molecules involved in the pathogenesis of cardiovascular disease (348).  
Furthermore, evidence from analysis of mouse and human vascular smooth 
muscle cells (VSMCs) show that KL can reduce vascular calcification through its 
regulation of FGF23 signaling (361,404).  It has also been suggested that KL can 
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protect from spontaneous cardiac hypertrophy and remodeling in mice 
overexpressing TRPC6 by down-regulating TRPC6 membrane localization 
therefore decreasing TRPC6 dependent currents (276).  Most notably, a recent 
study has shown that low plasma KL levels are independently associated with 
CVD (405).  All of these studies suggest that KL is involved in CVD through its 
regulation of many pathways. This involvement may be intertwined with its 
association in CKD, which can lead to development of CVD (406). 
 
2.6.6 Diabetes 
Klotho’s regulation of insulin/IGF pathways suggests it may play a role in 
controlling glucose metabolism. However, despite insulin resistance in KL 
overexpressing mice, there was no increase in blood glucose levels (273).  In a 
chemically induced rat model of diabetes, it was shown that KL levels are 
decreased in the kidney, which was associated with poor renal function(407). 
These phenotypes were recoverable by treatment with blood glucose lowering 
insulin or phloridzin, or tiron, an antioxidant (407).  Both mechanisms of 
improving KL levels and renal function lowered levels of reactive oxygen species, 
suggesting that it was a decrease in oxidative stress that was responsible for 
rescuing KL (407).  The reduction in KL levels after chemically induced diabetes 
was confirmed in rats as well showing that the effect was not species specific 
(407).  It was also found that levels of renal KL in patients with diabetic 
nephropathy were reduced (408).  Immunoassay for KL levels confirmed the 
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lower levels of KL in human diabetic patients (409).  Whether these lower levels 
of KL are just a biomarker of disease or are involved in the pathology is 
uncertain, but it is possible that they are caused by the pro-inflammatory state 
associated with diabetes (410). 
 
2.7 Case Studies and Polymorphisms 
Large alterations in KL levels are not often seen in humans except in the 
case of late stage diseases making it difficult to ascertain the functional 
significance of KL in normal human function.  Examinations of infrequent 
occurrences such as case studies and polymorphisms in KL allow for a better 
understanding of KL disease risk in humans. While case studies offer insight into 
how extreme differences in KL levels can affect human pathologies, studies of 
polymorphisms, which can be found in coding and non-coding regions of KL 
(Figure 7), allow more information to be gathered on how smaller changes in KL 
function can affect risk of diseases in a larger population.   
 
2.7.1 Case study: Increased Circulating Klotho 
At 13 months of age, a child presented with poor linear growth and increasing 
head size and was diagnosed with a nutritional form of rickets (411).  After 
unsuccessful treatment with vitamin D2, further investigations revealed 
hypophosphatemia, increased phosphatase activity and elevated PTH (411).  The 
diagnosis was changed to hypophosphatemic rickets due to inappropriate renal 
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Figure 7. Location of KL Polymorphisms in Coding and Non-Coding 
Regions.  Polymorphisms in KL that are associated with disease risk have been 
identified in the promoter and exons 2, 3 and 4.  With the exception of KLVS, 
they consist of one SNP independently associated with one or more diseases. The 
KLVS is comprised of 6 SNPs that span exon 2 and the surrounding introns. 
Diagram from Shimoyama et al., 2009 (412). 
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phosphate losses and the patient was given 1,25(OH)2 vitamin D supplemented  
with phosphate salt, which improved her condition.  Despite improvements, by 
the age of 7 it was evident that PTH levels were increasing leading to 
hypercalcemia.  Surgical investigation of the neck revealed four-gland 
parathyroid hyperplasia, which prompted removal of 3.5 glands.  The patient 
remained stable until 19 years of age at which time more of the parathyroid 
gland, which had enlarged again, was removed. Despite sequencing of FGFR1, 
phosphate-regulating neutral endopeptidase, X-linked (PHEX), dentin matrix 
phosphoprotein 1 (DMP1) and FGF23, which are highly involved in pathways that 
regulate these symptoms no mutations were found in these genes.  Further 
investigations of the chromosomes showed that there was a translocation 
between chromosome 9 and 13.  A closer look at the translocation identified KL 
as the closest gene distal to the breakpoint on chromosome 13.  Since KL is able 
to regulate phosphate, calcium and vitamin D levels, it was a likely candidate as 
the affected gene. Further studies showed that plasma levels of KL were highly 
elevated compared to age and gender-matched controls (411).   This case study 
shows that marked up-regulation of KL can be just as detrimental as down-
regulation most likely due to its important role in ion homeostasis.  This suggests 
that targeting KL as a potential therapy may only be useful in diseases where KL 
levels are measurably declined and may require monitoring of KL levels to make 
sure they fall within normal parameters.   
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2.7.2 Case study: H193R Polymorphism 
  A 13-year-old female presented with elevated blood serum levels of 
calcium, phosphate, 1,25(OH)2-vitamin D and PTH (413).  Surgical examination 
revealed 4-gland hyperplasia and subsequently, part of the excess gland was 
removed.  The subtotal parathyroidectomy normalized PTH and calcium levels, 
but production of calcium-phosphorus continued to be elevated.  Further analysis 
revealed diffuse osteopenia, patchy sclerosis in the hands, feet, long bones and 
calvariae, and metacarpal periosteal reaction.  Calcification was present 
intracranially in the dura and carotid arteries but not in the parenchyma and was 
also present in the Achilles tendon (413).  Presence of tumoral calcinosis 
prompted examination of FGF23 levels, which were 150 to 550 fold higher than 
normal.  Mutational analysis to find the gene that was altered showed no 
differences in the calcium sensing receptor (CASR), UDP-N-acetyl-alpha-D-
galactosamine:polypeptide N-acetylgalactosaminyltransferase 3 (GALNT3) or 
FGF23, which have all been independently associated with similar symptoms.  
Further analysis led to the discovery that there was a nucleotide substitution in 
the KL gene leading to replacement of a histidine for an arginine at amino acid 
193 (413).  Examination of the H193R substitution revealed that this 
polymorphism led to decreased amounts of mature KL and less shed KL in the 
media.  It was found that this polymorphism reduced the formation of the KL-
FGFR-FGF23 signaling complex.  Interestingly, KL still interacted with FGFR1c 
at close to wild-type levels, but did not co-immunoprecipitate with FGF23 (413).  
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These findings suggest that it is the lack of functional KL-FGFR-FGF23 complex 
and subsequent downstream signaling that is responsible for the severe tumoral 
calcinosis presented in this case study.   
Of note, some of the phenotypes present in this case study of decreased 
functional KL parallel the phenotypes seen in the case study of increased KL 
levels. Specifically, both patients suffered from increased levels of PTH and 
parathyroid hyperplasia even though other blood serum counts trended in 
opposite directions. It is also worth noting that in both cases parathyroidectomy 
was capable of regulating symptoms.  Increases in PTH in the presence of 
decreased KL are expected because of the inhibitory effect of KL on PTH 
secretion. Increases of PTH in the presence of increased levels of KL, however, 
suggest that the regulatory mechanisms for this pathway are more complicated 
than currently understood.  
 
2.7.3 Polymorphism of the Promoter: G-395A  
Evidence from hypermethylation of the KL promoter support the 
hypothesis that alterations in KL promoter activity can lead to disease. Therefore, 
it is not surprising that a polymorphism in the promoter is associated with many 
changes in disease risk.  One polymorphism has been identified and its effect on 
KL function has been well studied. 
Many studies have analyzed the effect of the G-395A substitution on the 
risk of CVD and found that it leads to alterations in many risk factors associated 
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with CVD such as high blood pressure (414).  This increased association with risk 
factors leads to higher incidences of many types of CVD including coronary artery 
stenosis (415), essential hypertension (416), atherosclerotic coronary heart 
disease (417) and cardioembolisms in individuals with this polymorphism (418). 
Despite all of these increased risks for CVD, one study found that in older 
individuals (over 60 years) there was actually a lower incidence of coronary 
artery disease (419).  This suggests that age may be a factor in the effect of this 
polymorphism.   
The G-395A polymorphism has also been linked to disease progression 
and mortality in IgA nephropathy (420), which is closely linked to its affect in the 
cardiovascular system because it is also associated with early dysfunction of 
vascular access in hemodialysis patients (421). Patients that have undergone 
hemodialysis also have higher levels of uric acid if the G-395A polymorphism is 
expressed (412).  
Interestingly, the G-395A polymorphism is associated with higher bone 
mineral density especially in postmenopausal Japanese women (422).  This 
polymorphism has also been associated with osteocalcin levels (423).  On the 
contrary, other studies have found an association of this variant with decreased 
bone mineral density in women 65 and older (424) and with increased risk of 
knee osteoarthritis in women (425).  These differences could be due to variations 
in other polymorphisms or in the age of the patients studied.   
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Further studies suggest that there is also a link between G-395A and risk 
of diabetes.  Not only is the incidence of diabetes increased with the expression of 
this substitution (426), there are also alterations in lipid metabolism (427) and 
increased body mass index (BMI) (428) which are associated with risk of 
diabetes.  G-395A is also associated with secondary characteristics related to 
sickle cell anemia such as leg ulcers and priapism (429,430).  Lastly, this 
polymorphism can also lead to increased risk of kidney stones (431).   
The variety of diseases that the G-395A polymorphism is associated with is 
reminiscent of the klotho deficient mice that have a global phenotype affecting 
many different tissue types.  Evidence in HEK293 cells suggests that this 
polymorphism alters the DNA-protein interaction, which could lead to alterations 
in KL expression (424). It is possible that individuals with this variant have 
consistently lower levels of KL leading to the variety of effects reported.   
 
2.7.4 Polymorphisms in Non-coding regions  
Many of the polymorphisms in intron 1 of KL are not well studied either 
due to low frequency in the population or ethnic specificity of the variant.  One 
such polymorphism is strongly linked with hemodialysis mortality despite the 
fact that it is not located near an exon (432).  It is known that the first intron 
often serves a regulatory function, which could explain this effect.  Another 
possibility is that it is associated with other polymorphisms in the area creating a 
secondary effect due to other polymorphisms (432). Despite the unknown 
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mechanism by which this polymorphism is acting, it is shown that expression of 
the polymorphism does lead to decreased levels of KL in cultured cells known to 
express the variant (432).  This suggests there is a direct correlation between KL 
levels and hemodialysis survival.  A separate set of polymorphisms found in 
intron 1 and the surrounding 3’ untranslated region are associated with sickle cell 
osteonecrosis (433).  This further supports the idea that polymorphisms in this 
region are capable of regulating KL expression.  
A series of polymorphisms were also identified downstream of the last 
exon in the CA repeat region.  Although the associations were weak, there were 
age-related links to the amount of spondylosis in postmenopausal women.  This 
suggests the region downstream of exon5 can regulate KL’s expression and/or 
activity leading to these changes in disease risk seen in the polymorphisms (434). 
 
2.7.5 Polymorphisms in KL2 
Although many of the functions of KL have been associated with the KL1 
domain, the KL2 domain has been associated with KL’s regulation of 
TRPC1/VEGF membrane localization. It is possible that KL2 is important in 
other functions of KL, but due to the mRNA splice variant consisting of KL1, this 
portion of the extracellular domain is less studied. 
Despite the lack of information on the importance of the KL2 domain, 
there are polymorphisms in this domain that are associated with risk of disease 
development and disease outcome.  Many studies have linked one polymorphism 
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in particular, C1818T, with increased risk for a variety of diseases. For instance, 
this polymorphism is linked to sickle cell anemia as it is associated with increased 
prevalence of secondary illnesses (429) (430).  C1818T is also more highly 
expressed in individuals with metabolic disorder (435) and has also been 
associated with changes in metabolism that are concomitant with this disease 
such as higher levels of fasting glucose (414), high body fat ratios and low levels 
of high-density lipoprotein (HDL) (427).   
There are also studies linking this polymorphism to CVD showing that 
there is actually a lower prevalence of coronary artery disease in carriers under 
the age of 60 (419).  This beneficial effect of the C1818T is confirmed by an 
association with higher levels of nitric oxide in younger individuals (436) and 
leads to lower levels of low density lipoprotein in hemodialysis patients (412).  
Despite these positive effects on cardiovascular health, this variant is also 
associated with higher systolic blood pressure in younger individuals (427).  
Despite all of these associations with disease risk, there are no studies 
investigating how the C1818T changes KL protein function. 
Other polymorphisms in KL2 are less frequently studied, but have also 
been associated with disease risk. A polymorphism found in exon 4, C2998T, is 
associated with increased risk of knee osteoarthritis in both men and women in a 
Greek population (425).  A polymorphism in exon 3, rs3752472, is linked to 
increased calcium oxalate urolithiasis leading to an increased risk of kidney 
stones in a Han population from Eastern China (437).  Another polymorphism in 
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the 4th intron is associated with carotid atherosclerosis in hypertensive patients 
(438) and severity of end stage renal disease (439).  These polymorphisms are 
not well studied, which could be due to their low frequency in the population or 
their isolation to specific ethnic groups. Despite this, they still  
add valuable information about how alterations in KL can lead to increased risk 
for a variety of diseases.    
 
2.7.6 Polymorphisms in KL1 
The first extracellular domain of KL has been associated with many of the 
functions attributed to KL.  It is highly implicated in KL’s tumor suppressing  
functions as well as its ability to inhibit growth factor signaling.  Despite its 
importance, there is only one polymorphism cluster in KL1 that has been 
associated with altered risk of disease (Figure 8). 
The KLVS variant consists of 6 single nucleotide polymorphisms (SNPs) 
that are always found together. Three SNPs lie in introns and do not alter splicing 
and another substitution at nucleotide 1155 causes no change in amino acid 
designation.  However, the changes from phenyalanine to valine at amino acid 
352 (F352V) and cysteine to serine at amino acid 370 (C370S) result in 
substitutions that could alter protein function (Figure 2).    
Multiple studies show that humans heterozygous for the KLVS allele have 
an increased chance of survival by approximately 2 fold over the age of 75 (440-
442).   
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Figure 8. Association of KLVS with Disease Risk. Diagram showing 
outlining the associations of the KLVS variant with increased risk for different 
diseases.  Within diseases, studies are split into those showing an association and 
not. Whether individuals are homozygous (hom) or heterozygous (het) for the 
variant is also depicted. It can be seen from the outlined studies that many of the 
associations with increased risk of disease are limited to indivuals homozygous 
for KLVS. 
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One study also found a reduced representation of KLVS homozygotes after this 
age (442).  Further characterization of the variant revealed protective effects of 
heterozygosity after 81, despite reduced frequency of heterozygotes in the 
population before this age (441).  In independent studies, the KLVS variant has 
also been linked to an increased risk of cardiovascular disease and metabolic 
syndrome with a similar pattern of advantageous KLVS heterozygosity and 
increased disease risk associated with homozygosity (435,441,443,444).  This 
could be explained by KLVS’s regulation of factors that independently increase 
risk of these diseases such as HDL-Cholesterol and systolic blood pressure (441).   
There are also age-dependent increases in bone mineral density in both male and 
female heterozygotes, but presence of a homozygote disadvantage could not be 
determined due to the low frequency of that genotype (445,446).  Contrary to the 
other effects, heterozygosity for KLVS increases the risk of breast cancer 1, early 
onset (BRCA1) associated breast and ovarian cancer and decreases the risk in 
homozygous patients from an Ashkenazi Jewish population, but not in a larger 
cohort of European ancestry (447,448).    
Unlike most other variants, there are studies suggesting that KLVS does 
change protein function.  The first studies showing a difference in function 
suggested that the KL1 domain containing KLVS had a slight increase in 
secretion.  When isolated, the V substitution led to a large decrease in secretion of 
the KL1 domain, while the S substitution led to a marked increase (442).  The 
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intermediate phenotype of the KLVS suggested that there was intragenic 
complementation between the two substitutions correcting for the drastic 
decrease caused by the V variant (442).  The same study showed that a homolog 
of KLV led to decreased enzymatic activity suggesting that the V substitution may 
affect KL’s enzymatic function(442).  Further studies investigated the V variant’s 
ability to alter KL’s tumor suppressing activities.  These findings suggested that 
expression of the V substitution suppressed KL’s ability to inhibit colony 
formation and tumor growth (447).  This suggests that the VS polymorphism may 
lead to a drastic change in KL function. Despite these preliminary studies, it is of 
note that most of the drastic changes have been found in the KLV variant alone, 
but are absent or have not been studied in the physiologically relevant KLVS 
polymorphism. These studies also lack a mechanistic explanation of what 
pathways are altered by the KLVS leading to the increased risk of age-related 
diseases and longevity.  
 
3. HYPOTHESIS AND SPECIFIC AIMS 
As the percentage of the population over 65 increases, there is growing 
pressure to better understand the aging process so that we may target the 
pathways that lead to an increase development of many chronic diseases.  
Finding a way to attenuate the aging process and allowing a longer, and more 
importantly, healthier lifespan will lessen the amount of healthcare costs that go 
to treating these chronic diseases and make the later years of life more vibrant 
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and fulfilling. Investigation into the function of KL has provided insight into a 
protein that regulates many of the pathways associated with aging and holds 
promise into elucidating how these various pathways could work together to 
cause the aging phenotype. Our work will aid in this greater goal by providing 
mechanistic clarity of the function of KLVS. We hypothesize that the KLVS 
variant leads to differences in the basic biochemical characteristics of the KL 
protein that lead to differences in the function of KL resulting in increased risk 
of disease.  In order to investigate this hypothesis, the following specific aims 
were developed. 
 
3.1 Significant Aim 1: Investigate Whether KLVS Alters KL Processing 
This aim follows up on previous data suggesting that KLVS leads to alterations in 
the shedding of secreted KL to elucidate whether there are differences in the 
processing of full-length KLVS or in the individual substitutions it contains.  
 
3.2 Significant Aim 2: To Determine Whether The KLVS Variant 
Leads to Altered Function 
The results from this aim will elucidate whether the substitutions that comprise 
KLVS result in a KL with altered function as determined by its ability to 
homodimerize, form complexes with FGFR and FGF23 and have enzymatic 
activity. 
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CHAPTER 2: METHODS 
1. PLASMID DNA CLONING  
1.1 Plasmid Constructs 
1.1.1 KLVS Variant Constructs 
The full length KL complementary DNA (cDNA) in pcDNA 3.1 was kindly 
provided by Dr. Hal Dietz from Johns Hopkins University School of Medicine, 
Baltimore MD.  To construct polymorphic variants containing F352V, C370S, or 
both, site directed mutagenesis was performed per manufacturer’s instructions 
(Agilent Technologies Inc., Santa Clara CA) using the following sense and 
antisense primers (Integrated DNA Technologies): 
  
KL C370S:  
5’- AGGTGGGTCCAAAGCTAAGAGCAAAAAAGTC-3’ and  
5’- GACTTTTTTGCTCTTAGCTTTGGACCCACCT-3’ 
KL F352V: 
5’- TCTCAGATTCAGTAACATCAGGCAGAATAGA-3’ and 
5’- TCTATTCTGCCTGATGTTACTGAATCTGAGA-3’ 
 
 1.1.2 Truncated Klotho Constructs 
To create constructs of the KL variants (V, S, VS) without the 
transmembrane and cytoplasmic domains, the KL variant constructs and a 
previously created KL980 construct that lacks the transmembrane and 
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cytoplasmic domains were digested with restriction enzymes ClaI and AgeI.  The 
resulting pcDNA3.1 plasmid containing the majority of the KL variant was ligated 
to the smaller fragment lacking the C-terminal end of KL.  Successful ligation was 
confirmed by sequencing (Tufts DNA Sequencing Core). 
 
1.1.3 Klotho Constructs with GFP Tag 
To create constructs of KL variants with a C-terminal green fluorescent 
protein (GFP) tag both the created KL variant constructs (V, S or VS) and a 
previously created KLGFP construct (231) were digested with restriction enzymes 
AgeI and XhoI. The excised fragment from the KLGFP construct containing GFP 
cDNA was ligated into the linearized KL variant constructs.  Confirmation of 
correct product was performed by sequencing (Tufts DNA Sequencing Core). 
 
1.1.4 Klotho Constructs with V5 Tag 
To create constructs of the KL variants (V, S, VS) with a C-terminal V5 tag, 
the KL variant constructs and a previously created KLV5 construct (231) were 
digested with restriction enzymes ClaI and AgeI.  The resulting pcDNA3.1 
plasmid containing the majority of the KL variant was ligated to the small 
fragment containing the truncated C-terminal end of KL containing a V5 tag.  
Successful ligation was confirmed by sequencing (Tufts DNA Sequencing Core). 
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1.2 Site Directed Mutagenesis 
Site directed mutagenesis was used to introduce point mutations into exon 
1 of the KL gene.  The mutagenesis experiments were carried out using 
QuikChange Mutagenesis Kit (Stratagene) according to the manufacturer’s 
protocol.  This procedure included using a denaturing temperature of 95°C and 
an elongation time of 16 minutes at 68°C.  After mutagenesis, the samples were 
digested with Dpn1 endonuclease at 37°C for 1 hour to remove any remaining 
parental DNA.  Digestion was followed by transformation into competent cells to 
screen for DNA containing the desired mutation. 
 
1.3 Restriction Enzyme Digest 
Restriction enzymes and accompanying buffers were acquired from New 
England Biolabs (NEB).  These enzymes were used to excise vectors and inserts 
from DNA for ligation and to confirm that plasmids contained the correct cDNA.  
Buffer conditions were chosen based on information gathered from the NEB 
website Double Digest Finder.  Approximately 4µg of DNA was mixed with 1µL of 
the appropriate restriction enzymes and 2µL of 10x buffer.  The mixture was 
brought up to 20µL with HyClone HyPure Molecular Biology Grade water 
(Thermo Scientific) and incubated at 37°C overnight for complete digestion.  
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1.4 DNA Ligation 
Ligations were performed to join excised inserts and vectors together 
using the Fast-Link Ligation Kit (Epicentre) per manufacturer’s protocol.  In the 
process of troubleshooting, some ligations were performed at 16°C overnight 
instead of 15 minutes at room temperature.  After ligation, the products were 
transformed into competent bacterial cells for selection of successful ligation 
products.     
 
1.5 Agarose DNA Gel Electrophoresis 
Samples were run on agarose gel electrophoresis in order to separate 
restriction enzyme products by molecular size.  One percent agarose gels were 
prepared from Genepure LE Quick Dissolve Agarose (ISC BioExpress) and TBE 
buffer (108g tris-base, 55g boric acid, 40mL 0.5M EDTA in 5L Millipore H2O).  
The mixture of agarose and TBE is heated in a microwave to ensure that all the 
agarose is dissolved.  Afterwards, approximately 0.5mg/µL Ethidium bromide is 
added to the solution to allow for visualization of DNA fragments. The resulting 
mixture is poured into a gel casting tray until hardened.  DNA samples of 1-2µg 
mixed with 6x Blue/Orange Loading Dye (Promega) were loaded into each well 
and separated by electrophoresis for approximately 30 minutes at 100V.  A 1 kb 
ladder (Promega) was run alongside the samples in order to allow for 
identification of the molecular weights of the bands.  The bands were visualized 
under a UV light box.      
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1.6 DNA Gel Extraction 
Gel extraction was used to retrieve restriction enzyme digested DNA 
fragments that had been separated out on agarose gels. To this end, the 
StrataPrep DNA Gel Extraction Kit (Stratagene) was used according to 
manufacturer’s protocol.  After elution, DNA was stored in elution buffer at -20°C 
until used. 
 
1.7 DNA Sequencing 
The sequences of all cloned plasmids were verified at the Tufts University 
Core Facility DNA Sequencing Lab, Boston, MA. 
 
2. PLASMID DNA PREPARATION 
2.1 Bacterial Transformation 
Bacterial transformation was used to introduce plasmid DNA into 
competent bacterial cells.  This was done to screen for successfully cloned 
plasmids containing antibiotic resistance genes that allow their growth on 
antibiotic supplemented plates.  Transformation was also done to amplify 
plasmids in order to obtain large amounts of DNA for experiments.  For 
transformation, plasmid DNA was transformed into NEB Turbo Competent E. 
coli (High Efficiency) cells (New England Biolabs) using the heat shock method.  
Fifty microliters of competent cells were incubated with 2-5µg of plasmid DNA on 
ice for 15min, and then the samples were heated at 420C for 45 seconds, and then 
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put back on ice for 2min.  Nine hundred microliters of LB-media (MP 
Biomedicals) was then added to the cells and they were incubated at 370C for 1 
hour in an environmental shaker at 200 rpm.  Afterwards, the cells were quickly 
centrifuged for a few seconds at 16,873xg (Eppendorf 5418 Microcentrifuge), and 
the supernatant was removed.  The cells were resuspended in 100µL of fresh LB-
then the cell suspension was spread onto 0.5mg/mL ampicillin agar plates 
prepared using LB-Agar (MP Biomedicals) and incubated in a 370C incubator 
overnight to allow colony formation. 
 
2.2 Minipreps 
Minipreps were used to extract and purify plasmid DNA at a small scale. 
Transformed bacterial colonies were selected from agar plates and were 
transferred into 4mL of LB broth containing 0.5mg/mL ampicillin.  The resulting 
inoculations were incubated at 37°C and 200 rpm in an environmental shaker. 
After overnight incubation, DNA was purified from the bacterial culture using the 
QIAprep Spin Miniprep kit (Qiagen) according to manufacturer’s protocol.  After 
elution, DNA concentration was determined and the resulting DNA was stored at 
-20°C until used. 
 
2.3 Midipreps 
Midipreps were used to extract and purify plasmid DNA at a larger scale. 
Transformed bacterial colonies were selected from agar plates and were 
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transferred into 100mL of LB broth containing 0.5mg/mL ampicillin.  The 
resulting inoculations were incubated at 37°C and 200 rpm in an environmental 
shaker overnight. The next day, DNA was purified from the bacterial culture 
using the Wizard Plus Midiprep Purification System (Promega) in accordance 
with manufacturer’s protocols.  Resulting DNA concentration was determined 
and the samples were stored at -20°C until used. 
 
2.4 DNA Spectrophotometry 
Quantification of purified DNA was determined by use of an Eppendorf 
Biophotometer.  Briefly, the purified DNA was diluted 1:50 with Millipore H20 
and absorbance values were read at 260 and 280 nm.  The measurement at 
260nm was used to measure the concentration of DNA and measurement at 280 
measured the concentration of protein contaminants and the 260/280 ratio was 
used to estimate the purity of the DNA.  Samples were considered pure if the ratio 
was between 1.8 and 2.0. 
 
3. CELL CULTURE 
3.1 Maintenance of Cell Cultures 
3.1.1 Human Embryonic Kidney (HEK) 293 Cells 
HEK293 cells were purchased from the American Type Culture Collection 
(ATCC).  Purchased cells were cultured in 10cm plates in Dulbecco’s modified 
Eagle’s media (DMEM) (CellGro) supplemented with 10% fetal bovine serum 
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(FBS) (Atlanta Biologicals) and 1% penicillin-streptomycin (CellGro) at 37°C and 
5% CO2.  Cells are grown until they reach 70-80% confluency at which point they 
are split (approximately every 3 to 4 days).  To split, cells are washed with 
Dulbecco’s phosphate buffered saline (DPBS) and then cell adhesion proteins are 
removed by incubation with 0.25% trypsin (CellGro) for 5 minutes at 37°C.  
Afterwards, 9mL of growth media is added to cells and pipetted up and down to 
dislodge cells.  The cell suspension is transferred to a 15mL centrifuge tube (BD 
Falcon) and centrifuged at 259g in a Beckman Coulter Allegra 21R centrifuge for 
5min.  The supernatant is removed, and the cells are re-suspended in 10mL of 
growth media.  One milliliter of the re-suspended cells is then added to a 10cm 
plate to propagate as the next passage of cells in 10mL of growth media.  To 
freeze cells for storage, the same process of trypsinization and spinning is 
undertaken, but instead of resuspension in growth media, the cells are 
resuspended in a freezing media containing 70% DMEM, 20%FBS and 10% 
dimethyl sulfoxide (DMSO).  After resuspension, 1 mL aliquots are transferred to 
cryogenic tubes (Corning) and then put in an isopropanol bath at -80°C 
overnight.   The next day, the cells are transferred to a liquid nitrogen tank for 
permanent storage until used. 
 
3.1.2 HEK Stable Cells 
   HEK293 cells stably overexpressing KL with a N-terminal Gaussia 
luciferase tag (provided by Dr. Cidi Chen) or overexpressing KLWT or VS 980 
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were made by the filter selection method. To do so, HEK293 cell were split into 2-
3 10-centimeter plates, enough to prepare the stable cell line and one extra for a 
control plate.  The day after splitting, the appropriate plasmids were transfected 
into separate plates at 10 µg DNA each. Two days after transfection, the media 
was changed to 10mL of growth media supplemented with 800µg/mL Geneticin 
(G418) (CellGro).  Cells are monitored over time and are maintained and split as 
needed until all of the cells on the control plate that do not contain G418 
resistance are dead. At this time, all remaining cells should contain the plasmid, 
which confers G418 resistance.  The remaining 10 cm plates are then split at 
multiple dilutions (1:50, 1:100, 1:200, 1:500, 1:1000) and analyzed for formation 
of single colonies once the cells have attached. Once single colonies have formed, 
they are picked from the plate using filter paper soaked in .25% trypsin (CellGro) 
and placed in a 6-well plate containing 2 mL of growth media supplemented with 
G418.  At least 10 colonies are picked to ensure that at least one colony is stably 
transfected with the appropriate plasmid.  Cells are maintained in G418 
supplemented growth media until they reach confluency at which point they are 
trypsinized and transferred to a 10 cm plate. Once the 10 cm plate has reached 
70-80% confluency, the cells are harvested to test for proper insertion of the 
plasmid of interest by western blotting.  The clones that tested positive were 
selected and expanded.  Frozen stocks are prepared and stored in liquid nitrogen 
as described above.   
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3.2 Transfection 
Transient transfection was used to introduce plasmid DNA into 
mammalian cells.  During cell division, the plasmid will amplify and large 
quantities of the desired DNA product will be synthesized.  For the experiments, 
plasmid DNA was transfected into cells using the Nanofect (Qiagen) polymer as a 
carrier.  Cells were split with 0.25% trypsin-EDTA (CellGro) into 6-well or 12-well 
tissue plates (Corning) at 1x105 cells per 6 well or 1x103 cells per 12 well the day 
before transfection.  The next day, a transfection mix consisting of 100µL Opti-
MEM, 6µL Nanofect and 2µg of total DNA for each 6-well or 50µL Opti-MEM, 
3µL Nanofect and 1 µg DNA for each 12-well was prepared. The mix was 
incubated for 15min at room temperature for the formation of transfection 
complexes.  After 15min, the transfection mix was added to the cells.  Twenty-
four hours after transfection, cells and media were harvested for experiments. 
 
3.3 Sample Preparation 
3.3.1 Preparation of Cell Lysates 
Cell lysates were collected and prepared for protein analysis in various 
experiments. Transfected cells were washed 1x with DPBS and then lysed with 
either 250µL (6-well) or 150µL (12-well) of RIPA lysis buffer (150 mM NaCl, 1% 
Triton X-100, 0.5 % Deoxycholate, 0.1 % SDS, 50 mM Tris pH 7.5) containing 
protease inhibitors (Roche) and phosphatase inhibitors (Roche) when needed.  
Lysates were pipetted up and down to facilitate complete lysis and were 
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transferred into 1.5 mL conical tubes. Resulting samples were centrifuged at 
16,000xg for 15 minutes after which the supernatant was collected and stored at -
20°C until use. 
 
3.3.2 Preparation of Media Samples 
Media samples were collected and prepared to analyze proteins in the 
extracellular space of transfected cells. Media was collected and debris was 
removed by centrifugation at 2,000xg after which the supernatant was moved to 
a new 1.5 mL tube.  Bovine serum albumin (BSA) was added to the samples in 
order to adjust to a final protein concentration of 10µg/mL.  Cold (4°C) 
trichloroacetic acid (TCA) was added to a final concentration of 25% then the 
mixture was incubated at -20°C for 5 minutes and then at 4°C overnight. After 
incubation, the samples were centrifuged at 16,000xg and the supernatant was 
removed. The resulting pellet was washed 3 times with ice-cold acetone with 5-
minute centrifugations.  The pellet was dried at 98°C for 5 minutes and then 
dissolved in 2x Laemmli sample buffer.  After resuspension half of the mixture 
was used for Sodium Dodecyl Sulfate (SDS)- Polyacrylamide Gel Electophoresis 
(PAGE) separation and the remaining sample was stored at -20°C until use. 
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4. PROTEIN ANALYSIS 
4. 1 Bicinchoninic Acid (BCA) Assay 
Protein concentration of cell lysates was measured by BCA analysis 
following the BCA protein assay kit (Pierce).  This colorimetric assay relies on the 
reduction of copper ions to cuprous ions by proteins in an alkaline media.  The 
cuprous ions can then be detected by their chelation with two molecules of BCA, 
which forms a purple colored product detectable at a wavelength of 562 nm.  This 
allows for the amount of protein present in a sample to be detected by analyzing 
the intensity of the readout at 562 nm.  The 562 nm absorbance of samples and 
standards was read in the Promega Glomax Multi Detection System plate reader. 
 
4.2 Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis  
Sodium Dodecyl Sulfate (SDS) Polyacrylamide Gel Electrophoresis 
(PAGE) was used to separate proteins by molecular weight.  Ten percent Tris-
Glycine gels were prepared with the Bio-Rad Mini-Protean Tetra System 
according to the recipe calculated by the SDS-PAGE website 
(http://www.changbioscience.com/calculator/sdspc.htm).  The gels were 
prepared using electrophoresis grade water (Fisher), 30% UltraPure Protogel 
(National Diagnostics), 10% Sodium Dodecyl Sulfate (Fisher), 10% Ammonium 
Persulfate (Sigma), TEMED (Sigma) and Tris-HCl (Fisher).  Protein samples 
were denatured in 5x Laemmli buffer (250mM Tris-HCl (pH 6.8), 10% SDS, 30% 
Glycerol, 5% beta mercaptoethanol, 0.02% bromophenol blue) and heated at 
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98°C for 5 minutes.  Twenty micrograms of protein samples were loaded into 
each lane of the Tris-Glycine gels and proteins separated in 1x Tris-Glycine SDS-
PAGE running buffer at 150 volts for 90 minutes.  The Fisher Bioreagent EZ-Run 
Protein Marker was loaded as a protein ladder in order to estimate the molecular 
weight of the visualized protein bands.   
 
4.3 Protein Transfer 
Proteins separated by SDS-PAGE were transferred to nitrocellulose 
membranes for further analysis via western blotting.  Proteins were transferred 
from the Tris-Glycine gels to 0.4µM Immobilon Hybridization nitrocellulose 
membranes (Millipore) at 100 V for 120 minutes in 1x Transfer Buffer (25mM 
Tris Base, 192mM glycine, 20% Methanol).  After transfer, membranes were 
stained with PonceauS (0.1% PonceauS in 5% glacial acetic acid) to confirm 
successful transfer. 
 
4.4 Western Blots 
Western blot analysis was performed on separated proteins present on 
nitrocellulose membranes.  The membranes were incubated twice for 15 minutes 
in 5% non-fat dry milk powder in TBS/T (50 mM Tris, 150 mM NaCl and 0.1% 
(v/v) Tween 20).  After blocking, the membrane was incubated in primary 
antibody overnight.  After incubation, the membranes were washed three times 
for 10 minutes with TBS/T, followed by the addition of a secondary antibody for 1 
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hour.  After the secondary antibody incubation, the membranes were washed four 
times for 15min each with TBS/T.  Finally, the Supersignal West Pico 
Chemiluminescent Substrate (Thermo scientific) or the Immobilon Western 
Chemiluminescent HRP Substrate (Millipore) was added to the membrane for 
5min, depending on the intensity of the signal desired.  The blots were then 
developed on Phoenix Research Products F-BX810 Blue X-Ray Films. 
 
4.5 Western Blot Antibodies 
Primary antibodies used for western blots were prepared in TBS-T with 
0.03% sodium azide and 3% bovine serum albumin (BSA).  For detection of KL, 
the rat monoclonal antibody KM2076 (Cosmo Bio Co., Ltd., Japan) was used at a 
dilution of 1:2000.  Mouse anti-β-tubulin (1:10,000) (Invitrogen, Grand Island 
NY) was used to stain tubulin, which served as a loading control, and dynamin 
was detected with mouse anti-Dynamin1 (1:10,000)(Abcam, Cambridge MA).  
FGFR1C-V5 was detected using a mouse monoclonal antibody against the V5 tag 
(1:5000)(Sigma) and phosphorylated ERK (1:10,000) and total ERK (1:1000) 
were detected using antibodies obtained from Sigma Aldrich and Cell Signaling 
Technologies, respectively. Appropriate horseradish peroxidase (HRP)-
conjugated secondary antibodies were obtained from KPL and were used at a 
dilution of 1:10,000. 
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5. ANALYSIS OF KLOTHO PROCESSING 
5. 1 Shedding Assay 
The shedding assay was used to analyze the amount of total KL protein 
that is shed into the media. To accomplish this, cells were transfected with full-
length wildtype KL (KLWT) or KL containing either one or both of the mutations.  
Twenty-four hours after transfection, cells were washed with Dulbecco’s 
Phosphate Buffered Saline (Mediatech Inc.) and incubated in serum-free DMEM 
for 24 hours.   Media was collected as described above and ran out on SDS-PAGE 
for western blotting analysis.  After the media collection, lysate was collected as 
described above and proteins were separated on SDS-PAGE for western blotting. 
 
5.2 Gaussia Luciferase Assay 
In order to look for compounds that alter KL shedding, HEK 293 cells 
stably overexpressing KL with a C-terminal Gaussia luciferase tag were tested for 
alterations in luciferase activity in both media and lysates of treated cells using 
the BrightGlo Luciferase Assay System (Promega).  Briefly, One hundred 
microliters of lysate or media collected from 6-well plates were added to a 96-well 
white plate.  Directly before reading, 100 µL of the BrightGlo Luciferase Substrate 
was added and then the plate was analyzed for changes in levels of luminescence 
on the Promega Glomax Multi Detection System plate reader. 
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5.3 MT-1 Chemical Treatment 
To determine whether polymorphism changes are due to protein 
misfolding, transfected cells were treated with MT-1, (5 µM; provided by Dr. Gal 
Bitan at UCLA) or control media immediately after transfection.  MT-1 acts as a 
chemical chaperone to help correct proteins misfolding and restore normal 
trafficking. After 48 hours lysate and media were collected and analyzed by 
western blotting (as above).  
 
5.4 Analysis of Klotho Half-life 
Half-life analysis was performed to analyze the effects the variants have on 
the degradation and processing of KL.  Use of biotinylation to measure half-life 
was first described by Fimbel et al. in an in vivo model (449).  This assay was 
developed in order to use biotin to measure half-life in a cell-based system. To 
achieve this, HEK 293 cells were transfected as described above. Twenty-four 
hours later, cells were washed twice with DPBS and incubated with a 1mM 
solution of cell permeable NHS-SS-Biotin (Pierce) containing 0.1% DMSO for 30 
minutes at room temperature. Afterwards, biotinylation was quenched by 
washing the cells twice with serum-free DMEM.  Cells were returned to DMEM 
containing serum and incubated at 37°C for the indicated time points.  At each 
time point, the media was aspirated from the cells and cell lysates were collected 
as described above.  After collection and centrifugation, the BCA Protein Assay 
(Pierce) was used to determine the protein concentration of the samples.  Then 
 89 
100 µg of protein from each sample was incubated at 4°C with neutravidin beads 
(Thermo Scientific) overnight in order to pull down all biotinylated proteins. The 
bound protein was then eluted from the beads by incubating in 2x Laemmli 
sample buffer and separated on 10% acrylamide SDS-PAGE. 
 
5.5 Membrane Biotinylation  
Cells were co-transfected with pcDNA3.1 empty vector (EV) or dominant 
negative dynamin (DN) and one of the KL variants. After 24 hours, the cells were 
put on ice, washed twice with ice-cold DPBS and incubated with a 1 mM solution 
of cell impermeable Sulfo-NHS-SS-Biotin (Pierce) for 30 minutes at 4°C.  After 
collection and centrifugation, the BCA Protein Assay (Pierce) was used to 
determine the protein concentration of the samples.    Then 100 µg of protein 
from each sample was incubated at 4°C with neutravidin beads (Thermo 
Scientific) overnight in order to pull down all biotinylated proteins. The bound 
protein was then eluted from the beads by incubating in 2x Laemmli sample 
buffer and separated on 10% acrylamide SDS-PAGE. 
 
5.6 SORLA Effects on KL Trafficking 
If the V variant leads to increased endocytosis, it may be possible to rescue 
its decreased shedding by directing the endocytosed protein towards recycling 
endosomes instead of to the late endosomes where it is targeted for degradation 
by the lysosomes.  To test this, HEK 293 cells were co-transfected with KLWT or 
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the variants and SORLA, a sorting receptor that regulates trafficking and 
processing of proteins sending them towards the recycling endosome.  The media 
and lysate were collected as described previously for analyzing changes in 
shedding and processed for western blotting.   
 
5.7 Immunofluorescence 
Immunofluorescence was performed to elucidate and compare the 
subcellular location of the variants.  HEK 293 cells were grown and transfected 
onto autoclaved, circular 18mm diameter, No.1 (0.13-0.16mm thick), cover 
glasses (Fisher) in 6-well plates with either KLWT-GFP or KL-GFP expressing the 
variants. Forty-eight hours after transfection, the cells were washed twice with 
DPBS and fixed with ice cold 100% ethanol for 10 min.  After fixation, cells were 
again washed twice with 1x DPBS for 5min.  Cells were blocked and 
permeabilized with blocking media (0.5% BSA, 0.1% Triton X-100 in 1x DPBS) 
for 10min except when cells were to be stained for plasma membrane. Plasma 
membrane samples were not permeabilized, and so were blocked with the 
antibody diluent, which is the blocking media without Triton X-100.  After 
blocking, cells were incubated with primary antibody for one hour.  Primary 
antibodies were diluted in antibody diluent at the following dilutions: Plasma 
membrane, wheat germ agglutinin (WGA), 1:200; endoplasmic reticulum (ER), 
calnexin, 1:200; Golgi, Giantin, 1:500; Lysosome, LAMP1, 1:500; and early 
endosome, EEA1, 1:500.  The amount of antibody used was just enough to cover 
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the entire coverslips.  All antibodies were purchased from Abcam.  Following 
primary antibody incubation, cells were washed twice with 1x DPBS for 5min.  
Then, cells were incubated in the dark with the secondary antibody, 1:200 
AlexaFlor 633, for 40min due to the light sensitivity of the antibody.  After 
incubation with the secondary antibody, cells were again washed twice with 1x 
DPBS for 5min.  Then, 300nM of the nuclear stain DAPI diluted in phosphate 
buffered saline (PBS) (Invitrogen) was added to the cells for 10 minutes, followed 
by two more washes with 1x DPBS for 5min.  A few drops of mounting media 
(90% glycerol in 100mM Tris (pH 8.0)), or alternatively the Prolong Gold Anti-
Fade Mounting Media (Invitrogen), were then placed onto Gold seal Rite-On 
Frosted Microslides (Thermo Scientific) with tweezers.  A little bit of pressure 
was applied to the cover glasses to ensure that the mounting solution covers the 
whole area without bubbles, after which, they were sealed with nail polish.  
Samples were kept at 4oC until ready for viewing under a microscope.  
 For obtaining images, the Nikon deconvolution wide-field epifluorescence 
system and then Zeiss LSM710-Live Duo Scan were used, which are located at the 
Boston University Core Laboratories & Facilities Cellular Imaging Core.  The 
excitation and emission wavelengths of the different fluorophores are as follows: 
GFP– 488/509nm (green), AlexaFlor 633 – 621/639 (red), and DAPI – 372/456 
(blue).  To excite the fluorophores, the lasers used include the 488nm FITC laser 
for KL-GFP green emission, 594nm Texas Red laser for the Alexa 633 sub-
cellular localization markers emission, and 405nm UV laser for the nuclear DAPI 
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emission. ImageJ was used to make a composite image of all three emissions and 
overlap between green and red, indicating overlap in localization, became yellow. 
 
6. KLOTHO FUNCTIONAL ASSAYS 
6.1 Live Cell Chemical Crosslinking 
Crosslinking was used to detect and identify protein-protein interactions 
between KL molecules. The crosslinker used was 
dithiobis[succinimidylpropionate] (DSP, Thermo Scientific).  This is a thiol-
cleavable and amine reactive agent.  For the experiments outlined below, live cell 
crosslinking was carried out as previously published (450).  Briefly, transiently 
transfected cells in 12 well plates were washed 2x with DPBS and then incubated 
with 100µM DSP for 30 minutes at room temperature.  Afterwards, the 
crosslinking solution was removed and the reaction was quenched by incubating 
with 50mM Tris buffer (pH 7.4) for 15 minutes. After quenching, cells were 
briefly washed with DPBS and collected for western blotting as described above 
except for use of Laemmli buffer without β-mercaptoethanol to preserve 
crosslinked interactions.    
 
6.2 Blue Native Gel Electrophoresis 
Blue Native gel electrophoresis was performed to separate proteins 
without denaturation.  This was done in order to determine whether the KL 
variants altered KL dimerization.  The Invitrogen NativePAGE Novex 4-16% Bis-
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Tris Gel system was used in accordance to the manufacturer’s protocol for the 
outlined experiments. Briefly, HEK 293T cells transfected as described above 
were solubilized in NativePAGE sample buffer containing 1% digitonin and 
complete protease inhibitor without EDTA (Roche) at 4°C. After determining 
protein concentration, an equal amount of protein from each sample was 
prepared for separation by mixing with 5% Coomassie G-250 (Invitrogen) to 
reach a final concentration of 1% Coomassie G-250. Pre-chilled anode and 
cathode buffers (dark blue and light blue) were used to run the gel. The dark blue 
cathode buffer was used until the dye front had moved through 1/3 of the gel and 
then was exchanged for the light blue cathode buffer until the completion of the 
run. After separation, the proteins were transferred onto an Immobilon 0.4µM 
PVDF membrane (Millipore).  To fix the proteins, the resulting PVDF membranes 
were incubated in 8% acetic acid and then the membranes were destained with 
methanol.  In parallel, the same samples were run in reducing conditions on 10% 
acrylamide SDS-PAGE gels in order to compare total expression of the 
transfected proteins.  Afterwards, both membranes were processed for western 
blotting as described above. 
 
6.3 Co-immunoprecipitation 
Co-immunoprecipitation studies were undertaken in order to determine 
whether the KLVS variant altered the protein interactions between KL and itself 
or other binding partners. To achieve this, HEK 293 cells were co-transfected 
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with combinations of KLWT and KLVS containing a V5 or GFP tag or with 
combinations of FGFR1c-V5 and EV, KLWT-GFP or KLVS-GFP. Twenty-four 
hours after transfection, cells were washed twice with ice-cold DPBS and 
collected in IP lysis buffer (1% Triton X-100, 0.01M Tris-HCl, 0.01M EDTA, 
0.05M NaCl, 0.05M NaF, pH 7.2) containing protease inhibitors.  After protein 
concentration was measured by BCA as described above, 100 µg of protein was 
loaded onto pre-washed V5 conjugated sepharose beads (Sigma, St. Louis MI) 
and incubated overnight at 4°C.  An identical set of lysates containing equal 
protein were incubated with anti-GFP (Roche) for 1 hour at 4°C before adding 
pre-washed protein A/G beads (Pierce) and incubating overnight 4°C.   After 
incubation, beads were washed and processed for SDS-PAGE as described above. 
 
6.4 FGF23 Assay 
To determine whether differences in KL-FGF interactions led to 
differences in downstream signaling, FGF23 assays were performed.  HEK 293 
cells were transfected with EV, KLWT or KLVS. Twenty-four hours after 
transfection, cells were incubated in serum free media for two hours and then 
either bFGF (basic fibroblast growth factor) or FGF23 (R&D Systems) was added 
to the wells to reach a concentration of 100ng/mL or 10ng/mL, respectively.  The 
cells were incubated for 15 minutes at 37°C and then were immediately washed in 
DPBS and lysed in RIPA containing protease and phosphatase inhibitors (Roche).  
After lysis, samples were prepared for SDS-PAGE as described above. 
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6.5 Enzymatic Assay: β-Glucuronidase Activity 
The glucuronidase assay was used to determine whether the VS variant led 
to changes in the enzymatic activity of KL.  Cells stably overexpressing the 980 
form of KLWT or KLVS or HEK 293 EV control cells were grown to confluency on 
10 cm plates.  Once confluency was reached, the media was aspirated, cells were 
washed with DPBS and serum free media was placed on the cells.  Twenty-four 
hours later, the media was collected and concentrated by use of Amicon Ultra 15 
centrifugal filters with a molecular weight cutoff of 50 kDa.  The filters were pre-
washed by centrifugation at 5000xg for 8 minutes with 10 mL of Millipore water.   
Afterwards, the collected media, which had already been spun to remove cell 
debris was added on to the filter and spun for 10 minutes at 5000xg.  After 
centrifugation, the concentrated media was collected and the process was 
repeated with the same filter for media from a total of 3 10cm plates.  This 
concentrated media was then analyzed by western blot to assure equal 
concentrations of KLWT and KLVS in their respective media.   
After concentration was determined, an equal amount of KLWT or KLVS was 
incubated with varying concentrations of 4-methylumbelliferyl β-D-glucuronide 
ranging from 0.0125 to 3.2 mM.  This compound is a substrate for the 
extracellular domain glucuronidase activity of KL whose hydrolysis results in 
a fluorescent product.  Readings were taken at 30min time points from 0- 2.5 
hours. Fluorescence was measured using a fluorometer at excitation wavelength 
of 360nm and emission wavelength of 470nm. Fluorescence readouts measured 
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in relative fluorescence units (RFU) were converted to µM concentration of 4-
methylumbelliferone product by analyzing fluorescence readouts for a serial 
dilution of 4-methylumbelliferone product.  The resulting information was 
plotted and the linear correlation between the RFU and µM product were 
determined so that the RFU values for the experimental conditions could be 
converted to µM 4-methylumbelliferone allowing for further analysis.   
 
7. DATA ANALYSIS AND STATISTICS 
Statistical analyses were performed with Graphpad Prism software version 
5.0.    Before further analysis, data sets were analyzed for significant outliers 
using the Grubbs Outlier Test.  Data sets containing 3 or more groups were 
analyzed using 1-way ANOVA.  Post-hoc Dunnet tests were performed when 
significance of p<0.05 was achieved.  Data sets containing only two groups were 
analyzed by student t-tests.   
Half-life data was analyzed by using the extra sum-of-squares F test to 
compare lines of best fit generated from a one-phase decay model.  Data was 
considered significant when a global comparison of Y0, K and plateau resulted in 
a rejection of the null hypothesis with a p<0.05.    
For analysis of glucuronidase data, first the concentration of 4-
methylumbelliferone product in each sample was determined.  To accomplish 
this, fluorescence readouts measured in RFU were converted to µM 
concentration of 4-methylumbelliferone product by analyzing fluorescence 
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readouts for a serial dilution of 4-methylumbelliferone product.  The resulting 
information was plotted and the linear correlation between the RFU and µM 
product were determined so that the RFU values for the experimental conditions 
could be converted to µM 4-methylumbelliferone allowing for further analysis. 
After this conversion, the concentration of 4-methylumbelliferone product was 
plotted over reaction time for EV, WT and VS and the initial velocity (v0) of each 
reaction was determined for every initial substrate concentration ([S0]) by 
calculating the slope of the resulting graphs. [S0] and v0 were then plotted to 
obtain the Lineweaver-Burke plot for the samples. From this plot, the Michaelis-
Menten constant (Km) and maximum velocity (vmax) were calculated using 
Graphpad Prism software. 
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CHAPTER III: RESULTS 
1. AIM 1: CHANGES IN KL PROCESSING DUE TO KLVS VARIANT 
1.1 Klotho Variant Constructs 
Constructs containing point mutations representing the substitutions 
present in the KLVS variant were used to further study how these two amino acid 
substitutions might affect the trafficking and function of KL.  To this end, 
constructs were generated that expressed the V substitution (KLV) and S 
substitution (KLS) each alone, as well as one that expressed both V and S 
substitutions (KLVS).  Constructs were also made that represent the extracellular 
domain of KL referred to as KL980 containing the same substitutions (V, S and 
VS) (Figure 9A).  This recombinant engineering allowed us to further investigate 
how the absence of the transmembrane and intracellular domains of KL may 
affect its function in a manner specific to these amino acid substitutions.  
Furthermore, constructs of KLV, KLS and KLVS were made with GFP fused at the 
C-terminus of the protein in order to allow for easy visualization of the protein 
with microscopy (Figure 9B).  This approach allowed for a detailed investigation 
of the subcellular location of KL and how it might be affected by the presence of 
substitutions. Constructs were also made containing a V5 tag at the KL C-
terminus (Figure 9C). This tag allowed for the isolation and detection of KL 
without a specific antibody and aided in co-immunoprecipitation, as well as 
depletion of KL from conditioned media. These constructs helped us to identify 
alterations in the trafficking and function of KL associated with the VS variant. 
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Figure 9. Diagram of KL Constructs. Diagram of the KL constructs 
prepared outlining location of tags and presence of truncations. (A) Constructs 
were made to represent the extracellular domain of KL lacking the intracellular 
C-terminus and membrane-spanning fragment.  The resulting construct consists 
of 980 amino acids leading to it being referred to as KL980. (B) Constructs of KL 
were made containing a C-terminal GFP tag (KLGFP) to allow for easy 
visualization of the protein via microscopy. (C) Constructs containing a C-
terminal V5 tag were prepared to allow for isolation and detection of KL without 
a specific antibody to the KL protein. D) A construct was prepared containing an 
N-terminal Gaussia Luciferase (GLuc) tag located after the signal sequence 
(depicted as dark grey portion on N-terminus) in order to visualized the KL shed 
into the media.  
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1.2 Expression of KLV Variant Leads to Decreased Shedding  
In previous studies, insertion of the VS polymorphism in a construct 
consisting solely of the KL1 portion of the extracellular domain revealed 
differential secretion (442) when compared to wildtype.  However, the effect of 
the two amino acid substitutions on the shedding of full-length KL was not 
investigated.  Since the full length 135kDa transmembrane protein is detected in 
cells and the 130kDa shed protein including both the KL1 and KL2 domains is 
detected in both blood and CSF, we reasoned that these protein fragments are 
likely to be the most physiologically relevant to investigate (230).   
To assess whether there are differences in the shedding of the 
transmembrane form, dependent upon the variant, HEK 293 cells were 
transfected with transmembrane KLWT, KLV, KLS or KLVS.  Shedding was 
measured by collecting conditioned serum free media and lysates from the 
transfected cells over a 24-hour period.  To correct for differences in KL construct 
expression, shedding was expressed as a ratio of extracellular (media) to 
intracellular (lysate) KL levels.  Compared to KLWT, the KLV variant displayed a 
46% decrease in the amount that was shed into the extracellular space (n=5, 
p<0.05) (Figure 10), similar to the difference reported previously in the literature 
(442).  Conversely, neither the KLS nor KLVS variant showed a significant 
difference in shedding from wild type.  The absence of a VS specific phenotype 
suggests that there is intragenic complementation in cis between the two 
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substitutions.  Expression of the KLS substitution can correct for the reduced 
shedding phenotype of KLV leading to a KLVS that is shed normally.  
 
1.3 KL Transmembrane Domain Necessary for Decrease in KLV 
Shedding  
To determine if transmembrane trafficking of KL through the trans golgi 
network is necessary for the shedding changes seen in the KL variants, we 
generated additional constructs of KL variants that lacked the intracellular and 
transmembrane domains.  These constructs, consisting of the N-terminal 980 
amino acids (KL980), resemble the extracellular portion that is usually shed from 
the membrane.  To determine whether there are still differences in secretion, 
KLWT 980 or KL980 containing one or both of the variants were transfected into 
HEK 293 cells.  Twenty-four hours after transfection, the media was changed to 
DMEM without serum and the resulting media and cell lysates were collected 
after 24 hours. The samples were analyzed for amounts of KL in lysate and media 
to obtain levels of intracellular and extracellular KL respectively.  The 
extracellular: intracellular ratio was calculated as a means to determine 
differences in secretion.  Unlike the full-length transmembrane KL, there is no 
difference in the secretion of KLV 980 compared to KLWT 980 (n=5) (Figure 11).  
This suggests its attachment to the membrane is necessary for the difference in 
shedding seen in the full-length protein. The lack of transmembrane domain does 
not significantly alter the secretion of any other variants, suggesting  
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Figure 10. KLV Dramatically Decreases Shedding. Shedding was 
examined by transfecting HEK 293 cells with wildtype (WT) KL or KL containing 
one or both of the amino acid substitutions in KLVS (V, S or VS).  Shedding 
differences were measured by western blot as change in the 
extracellar:intracellular KL protein ratio.  (A) Representative blot showing KL 
expression and β-tubulin loading control in the lysate (intracellular), and KL 
levels in the (B) media. (C) Quantification of band intensity was measured across 
multiple independent experiments. Graph represents the mean fold change of 
extracellular:intracellular KL (error bars are ± SEM; n=5; *p<0.05, ANOVA).      
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that the effect on the KLV is specific to the phenotype of this variant alone.   
It is known that absence or presence of a transmembrane domain can lead 
to alterations in glycosylation of proteins, which can alter their trafficking and 
function (451). Coupled with the results above, our data suggests that the 
phenotype associated with the KLV variant requires transmembrane-dependent 
processing of KL.  It is also possible that lack of membrane anchoring changes the 
binding partners of KLV that usually lead to increased KLV internalization.  For 
example, KL’s complex with TRPC1 and VEGFR2 leads to internalization of all 
the components including KL (318).  If the KLV has increased affinity for this 
complex, it could explain the increase in internalization.  Together, these results 
show that loss of KL’s transmembrane localization attenuates the shedding 
phenotype seen with the KLV, but does not alter other variants showing that it is 
not a non-specific effect. 
 
1.4 KLV Shedding Decrease is not Due to Misfolding 
1.4.1 MT-1 Increases KL Shedding Irrespective of Variant Expression  
MT-1 is a small molecule that acts as a chemical chaperone to help correct 
protein misfolding and restore normal trafficking. If the KLV variant leads to 
misfolded protein, treatment with MT-1 should restore normal trafficking of the 
protein and lead to a correction of the altered shedding seen with this variant. To 
test this, HEK 293 cells transfected with KLWT or KLV were treated with 5 µM 
MT-1 for 48 hours and then assessed for differences in shedding.  While MT-1 did 
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Figure 11. Truncation of KL Attenuates Shedding Differences.  
Shedding was evaluated by transfecting HEK 293 cells with the truncated 
extracellular KLWT980, or KL980 containing one or both of the amino acid 
substitutions in KLVS (V, S or VS).  Secretion differences were measured by 
western blot as a change in the extracellular: intracellular KL protein ratio.  (A) 
Representative blot showing KL980 expression and β-tubulin loading control in 
the lysate (intracellular), and KL980 levels in the (B) media.  (C) Quantification 
of band intensity was measured across multiple independent experiments. Graph 
represents the mean fold change of extracellular:intracellular KL (error bars are 
± SEM; n=3). 
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significantly increase KLV shedding, it also increased KLWT shedding by a 
similar magnitude (p<0.05, n=3) (Figure 12).  The results suggest that MT-1 is 
affecting the shedding of KL by a secondary mechanism unrelated to the amino 
acid change caused by the KLV substitution.  This could be due to a stabilization 
of KL folding unrelated to the KLV variant or stabilization of another protein that 
is involved in KL trafficking.  
 
1.4.2 Glycerol Treatment Can Not Rescue KLV Shedding Differences  
Previous studies have shown that glycerol treatment is capable of 
reversing the misfolding phenotype of mutated protein (452), therefore treatment 
with glycerol should allow normal trafficking of KLV if the protein is misfolded.  
To determine whether glycerol could correct the abnormally trafficked KLV, HEK 
293 cells transfected with either KLWT or KLV were treated with media 
containing 10% glycerol for 24 hours.  Afterwards, alterations in shedding were 
assessed by calculating the extracellular: intracellular ratio.  These calculations 
revealed that there was no effect of glycerol on the aberrant shedding of KLV 
(n=3) (Figure 13).  However, glycerol treatment did have an effect on overall KL 
expression.  It led to a decrease in the amount of KL present in the lysate and 
media of both KLWT and KLV (n=3, p<0.05, 2-way ANOVA).  Decreased KL 
expression suggests there may be cytotoxic effects of this dose of glycerol on HEK 
293 cells that alter the results or that glycerol acts on another protein that alters 
KL processing. 
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Figure 12. MT-1 Increases KL Shedding Irrespective of Variant 
Expression.  Shedding was evaluated after treatment of HEK293 cells 
transfected with KLWT or KL containing the V substitution with 5µM MT-1 or 
control media for 48 hours.  Shedding was evaluated by western blot as a change 
in the extracellular: intracellular KL protein ratio.  (A) Representaive blot 
showing KL expression in the lysate (intracellular) and media (extracellar) in the 
presence of 0 or 5 µM MT-1. (B) Quantification of band intensity was measured 
across multiple independent experiments. Graph represents the mean fold 
change of the extracellular:intracellular KL ratio (error bars are ± SEM; n=3, 
*p<0.05, ANOVA) Treatment of MT-1 led to an increase in KL shedding of KLWT 
and KLV irrespective of presence of the variant.  
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1.5 Screening for Modulators of KL Shedding 
1.5.1 Designing Screen to Discover Modulators of KL Shedding 
KL shedding into the extracellular space is necessary for many of the 
functions of KL.  Therefore it is important to maintain normal trafficking and 
shedding of the protein.  It is possible that mediators of KL shedding could also 
correct the detrimental phenotype of the KLV variant.  To this end, we created a 
stable cell line overexpressing a KL molecule with a N-terminal Gaussia 
Luciferase tag following the signal sequence (GLucKL) (Figure 9D).  This 
construct allowed for visualization of the amount of KL shed into the media. In 
the end, two stable lines were tested for expression of the construct by assessing 
luciferase activity in the lysate and media of the cells (n=3) (Figure 14).  Both cell 
lines expressed KL in the lysate and in the media suggesting they were good 
candidates for use in screening of compounds.  
Since insulin is a known mediator of KL shedding (231), it was used as a 
positive control to assess the validity of the GLucKL assay.  To do this, GLucKL 
stable cells were treated with 0.2 µg/mL insulin in serum free media for 0, .5, 1, 2, 
4 or 6 hours or with serum free media without insulin for the same time.  After 
treatment, both media and lysate were collected and tested for luciferase activity.  
During this time period, there was a linear relationship between the amount of 
GLucKL in the media and time cells were incubated with insulin (n=3) (Figure 
15).  Although this relationship is expected to plateau at some time point, within 
this range there is still a positive linear correlation.  This could be due to a 
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Figure 13. Glycerol Treatment Can Not Rescue KLV Shedding 
Differences.  Shedding was evaluated after treatment of HEK293 cells 
transfected with KLWT or KL containing the V substitution with 10% glycerol or 
control media for 24 hours.  Shedding was evaluated by western blot as a change 
in the extracellular: intracellular KL protein ratio.  (A) Representaive blot 
showing KL expression in the lysate (intracellular) and media (extracellar) in the 
presence of 0 or 10% glycerol. (B) Quantification of band intensity was measured 
across multiple independent experiments. Graph represents the mean fold 
change of the extracellular:intracellular KL ratio (error bars are ± SEM; n=3). (C) 
Graph represents change in densitometric intensity of KL in the lysate (error bars 
are ± SEM; n=3). (D) Graph represents change in densitometric intensity of KL 
in the media (error bars are ± SEM; n=3).  Glycerol treatment did not correct for 
KLV alterations in shedding, but did lead to a decrease in the amount of KL 
expression of both KLWT and KLV (p<0.05, 2-way ANOVA). 
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longer half-life of GLucKL in the media versus half-life of intracellular KL 
resulting in a buildup of GLucKL over time.  Despite lack of plateau, we were able 
to see increase in KL shedding with treatment of insulin. 
 
1.5.2 IGF-2 Increases KL Shedding 
The validated assay was used to determine whether other IGFs could also 
have an effect on KL shedding.  In particular, we examined the ability of IGF2 to 
increase the shedding of KL.  To this end, cells stably expressing GLucKL were 
treated with 0.1 µg insulin or IGF-2 or with serum free media as a negative 
control.  All treatments were added to GLucKL cells for 15 minutes or 6 hours 
(Figure 16).  Changes in shedding due to insulin could be seen starting at 15 
minutes and were amplified at 6 hours as there was a 100% increase in the 
shedding compared to control between these times (n=3, p<0.05).  The IGF-2 
increase in shedding was not significant at 15 minutes despite the average percent 
change being greater than that seen by insulin treatment (194.48% increase with 
insulin versus 240.05% increase with IGF2), although there was a trend towards 
significance (n=3, p=0.06).  At 6 hours, however, there was a significant increase 
in shedding compared to control and the magnitude of the change was larger 
than that seen by insulin treatment (n=3, p<0.05).   
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Figure 14. Designing Screen to Discover Modulators of KL Shedding.  
Shedding of HEK 293 cell lines stably transfected with gaussia luciferase KL 
(GLucKL) were evaluated by measuring relative luciferase activity in the media 
and lysate.  Bar graph depicts quantification of relative luciferase units measured 
over independent experiments for expression of the construct (error bars are ± 
SEM; n=3). Two cell lines GLucKL 2 and GLucKL8 were chosen for their high 
expression of GLucKL constructs as evaluated by luciferase activity. 
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These results suggest that other growth factors are also capable of regulating KL 
shedding.  Compounds found by this screening method could be tested for their 
ability to increase the shedding of KLV leading to a more normally trafficked 
protein.  This could potentially elucidate the mechanisms of decreased KLV 
shedding as well as give insight into therapeutic targets that could increase serum 
levels of KL.  
 
1.6 KLV Expression Results in Decreased Half-life  
Altered secretion could be the result of changes in KL processing.  To 
begin investigation of this possibility we assessed variant half-life using 
biotinylation to measure changes in protein degradation (449).  The proteins of 
HEK 293 cells transfected with KLWT or the variants were biotinylated for 30 
minutes.  After quenching the reaction cells were allowed to incubate at 37°C 
before lysates were collected at time points from 30 minutes to 6 hours (Figure 
17).  Biotinylated proteins were isolated using neutravidin beads and changes in 
biotinylated KL were measured by western blotting to assess the amount of KL 
remaining as compared to the amount seen at time zero.  There was a decrease in 
the half-life of the KLV variant (t½=0.6554, r2 = .8245), compared to KLWT 
(t½=1.325, r2 = .7065, p<0.05), but no differences in KLS  (t½=2.036, r2 
=0.6021) or KLVS (t½=2.572, r2 = 0.6862) found by comparing non-linear 
regression models for one-phase decay through an extra sum-of-squares F test  
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Figure 15. Validating GLucKL as Screening Platform. To evaluate the 
validity of the GLucKL cell lines as a screening platform for discovering 
modulators of KL shedding, HEK 293 cell lines stably transfected with GLucKL 
were treated with 0.2 µg/mL insulin in serum free media for 0, .5, 1, 2, 4 or 6 
hours or with serum free media without insulin for the same time.  At each time 
point, media and lysate were collected and luciferase activity was measured.  
Graph represents quantitation of relative luciferase units at each time point 
measured over independent experiments (error bars are ± SEM; n=3).  Line 
represents line of best fit generated by GraphPad Prism Software. 
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(Figure 17).  These observations coincide with our previous results, further 
implicating the role of intragenic complementation: while the KLV variant leads 
to a decrease in half-life, the expression of the KLS variant attenuates the 
phenotype when expressed together in the KLVS variant.     
 
1.7 Membrane Localization of KL Variants 
1.7.1 KL Isoforms Result in Altered Membrane Localization  
To determine whether KL trafficking to and from the membrane was 
affected in the KL variants, we compared the amount of KLWT and KL variant on 
the membrane with and without endocytosis blocked by the presence of DN.  To 
assess changes in plasma membrane localization, cells co-transfected with either 
KLWT or variants and pCDNA 3.1 EV or DN were biotinylated at 4°C for 30 
minutes with a cell impermeable biotin.  The lower temperature slows 
internalization to ensure that membrane-bound proteins are biotinylated but not 
internalized.  After collection of lysates, biotinylated proteins were isolated and 
KL levels were measured by western blotting. The amount of KL on the 
membrane was normalized to total KL expression to correct for differences in 
construct expression.  When co-transfected with EV, the KLV variant shows a 
decrease in the amount of KL on the membrane compared to KLWT (n=4, 
p<0.05) (Figure 18A and B). 
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Figure 16. IGF-2 Increases KL Shedding.  HEK 293 cells stably expressing 
GLucKL were treated with 0.1 µg insulin or IGF-2 or with serum free media as a 
negative control.  All treatments were added to GLucKL cells for 15 minutes or 6 
hours after which lysate and media was collected and analyzed for luciferase 
activity.  Differences in shedding were determined by anaylizing the extracellular: 
intracellular ratio of each treatment group and comparing it to the untreated 
control. (A) Bar graph depicting changes in shedding after 15 minutes of insulin 
or IGF-2 treatment as compared to control serum free treatment (n=3, *p<0.05, 
ANOVA). (B) Bar graph showing differences in shedding after 6 hours of insulin 
or IGF-2 treatment as compared to serum free (error bars are ± SEM; n=3, 
*p<0.05, ANOVA). Both insulin and IGF-2 led to increases in KL shedding, 
although the increase in IGF-2, despite being a larger fold change, was not 
significant until 6 hours of treatment (p<0.05). 
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Conversely, KLS shows an increase in the amount on the membrane (n=5, 
p<0.05) (Figure 10A and B). This difference in membrane localization suggests 
that trafficking to or from the membrane could explain the altered shedding and 
half-life of the variants.  
 
1.7.2 KL Variants Alteration of Membrane Localization Attenuated by Inhibition 
of Endocytosis  
Co-transfection with DN allowed us to test whether the changes in 
membrane localization were due to alterations in trafficking to the membrane 
without having to account for differences in internalization of the variants.  In 
contrast to the pattern seen when the KL variants are co-transfected with EV, in 
the presence of DN, there are no significant differences in membrane localization 
(n=5) (Figure 18C). These findings suggest that changes in secretion and half-life 
are the result of altered endocytosis and that these changes are normalized when 
internalization is blocked. 
 
1.8 SORLA Does Not Alter KLVS Processing  
If the KLV variant leads to increased endocytosis, it may be possible to 
rescue its decreased shedding by guiding the endocytosed protein towards 
recycling endosomes instead of to the late endosomes where it is targeted for 
degradation by the lysosomes.  To test this, HEK 293 cells were co-transfected  
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Figure 17. KLV Decreases Protein Half-life. HEK 293T cells transfected 
with wild-type (WT) KL or KL containing one or two of the amino acid 
substitutions in KLVS (V, S or VS) were tested for changes in half-life of KL. Cells 
were biotinylated and half-life was assessed as amount of KL left 0.5, 1, 2, 4 or 6 
hours after biotinylation was quenched and cells were placed back at 37°C. (A) 
Representative western blot of lysates pulled down with neutravidin beads after 
biotinylation and probed for presence of KL protein. (B) Graph depicts half-life of 
KL variants represented by percent KL remaining over time (hrs) (error bars are 
± SEM; n=5).  Half-life values of variants measured by non-linear regression 
model of one-phase decay were as follows: KLWT- 1.33 hrs, KLV-0.66 hrs, KLS-
2.03 hrs and KLVS-2.53 hrs.    The non-linear regression of KLV was found to 
significantly differ from KLWT by using the extra sum-of-squares F test (n=5, 
p<0.05). 
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with KLWT or the variants and SORLA, a sorting receptor that regulates 
trafficking and processing of proteins sending them towards the recycling 
endosomes.  After transfection, media and lysate were collected to analyze 
differences in shedding caused by the presence of SORLA.  By measuring the fold 
change in the extracellular: intracellular ratio it was determined that there is no 
significant change in shedding due to SORLA expression (n=3) (Figure 19).  This 
result suggests that SORLA does not affect KL trafficking, although it does not 
rule out the possibility that there is altered endocytosis in the KLV variant or that 
another sorting molecule is involved.   
 
1.9 Altered Subecellular Localization of KL Variants in Endosomes 
Immunofluorescence experiments were employed to further elucidate any 
changes in subcellular localization caused by the KLVS variant.  To determine 
this, HEK 293 cells were transfected with either KLWT-GFP or KL-GFP 
expressing the variants and were stained for markers of varying subcellular 
compartments including wheat germ agglutinin (WGA) or cadherin (plasma 
membrane), GM130 (golgi), calnexin (endoplasmic reticulum), M6P (late 
endosome) and LAMP1 (lysosome).  All of the variants had a similar distribution 
mainly localized to the ER, golgi and late endosomes (Figure 20).  Although there 
is not a striking difference in the localization of the variants, there is a difference 
in the intensity of staining in the late endosome.  While there is increased 
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Figure 18. Blocking internalization differentially affects KL V and S 
variant membrane localization.    HEK 293T cells transfected with wild-type 
(WT) KL or KL containing one or two of the amino acid substitutions in KLVS (V, 
S or VS) in the presence of an empty vector (EV) or dominant negative dynamin 
(DN) construct were assessed for differences in membrane localization of KL.    
Membrane abundance was measured by membrane biotinylation and subsequent 
pull-down of biotinylated proteins with neutravidin beads.  (A) Representative 
western blot illustrating differences in membrane abundance of the KL variants 
in the presence of EV or DN compared to expression in total lysate as well as 
confirming expression of the DN construct. (B) Bar graph showing membrane 
abundance of KL co-transfected with EV normalized to total KL in cell lysate 
across multiple experiments (error bars are ± SEM; n=4, *p<0.05, ANOVA). (C) 
Bar graph depicting membrane localization of KL in the presence of DN 
normalized to amount of total KL in the cell lysate across multiple experiments 
(error bars are ± SEM; n=4, ANOVA). Changes in membrane localization due to 
KLV or KLS expression are normalized when dynamin-dependent endocytosis is 
blocked.     
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localization of the KLS variant in the late endosome as indicated by the increased 
yellow staining, the KLV variant has a decreased localization. This could be an 
indication of altered processing of the protein after endocytosis into the cell.  It is 
known that KL is present in exosomes found in the urine (453) so this increased 
localization of the KLS variant to the late endosomes could be a sign of an 
increased amount of KL being packaged in the microvesicles that are formed in 
the late endosomes. Increased presence of KL in the exosomes would lead to 
increased amount of KL in the media because these microvesicles are secreted 
into the media.  This could explain the increase in S seen in the media. Although 
it might be expected that there would be increased KLV in the late endosomes 
due to its increased endocytosis, its diminished presence could be explained by 
increased rates of trafficking to lysosomes where the protein would be degraded 
and not visible.  
 
2. AIM 2: KLVS VARIANT LEADS TO ALTERED KL FUNCTION 
2.1 KLVS Variant Alters KL Dimerization 
2.1.1 Alteration in Dimerization Assessed by Crosslinking 
  Dimerization can affect trafficking of proteins (454,455) and can be 
important in internalization of transmembrane proteins (456,457). Since KL 
forms dimers (230,231) and dimerization is important for the activity of many β-
glycosidases, the effect of the KL variants on dimerization was investigated by 
two different assays.  First, crosslinking was performed with a cell-permeable and 
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Figure 19. SORLA Does Not Affect KLVS Processing.  Shedding was 
examined by co-transfecting HEK 293 cells with wildtype (WT) KL or KL 
containing one or both of the amino acid substitutions in KLVS (V, S or VS) and 
SORLA.  Shedding differences were measured by western blot as change in the 
extracellar:intracellular KL protein ratio.   (A) Representative blot showing KL 
expression in the lysate and media of cells co-transfected with KL and EV.  (B) 
Representative blot showing KL expression in the lysate and media of cells co-
transfected with KL and SORLA.  (C) Quantification of band intensity was 
measured across multiple independent experiments. Graph represents the mean 
fold change of extracellular:intracellular KL in the presence or absence of SORLA 
(error bars are ± SEM; n=3).      
 
 121 
 
Figure 20. Altered Subecellular Localization of KL Variants in 
Endosomes.  Subcellular localization of KL was determined by transfecting 
HEK 293 cells with either KLWT-GFP or KL-GFP containing one or both of the 
amino acid substitutions in KLVS (V, S or VS) after which they were stained for 
one of the following subcellular compartment markers: wheat germ agglutinin 
(WGA) for plasma membrane (PM), calnexin for endoplasmic reticulum (ER), 
gm130 for golgi, LAMP1 for lysosomes (Lyso.) and M6P for late endosomes (Late 
Endo.). Subcellular compartment markers were visualized with AlexaFluor 633 
(red) and the cells were counterstained for the nuclear marker DAPI (blue). KL 
was visualized using the attached GFP tag (green).   Image J was used to make a 
composite of all three images and any overlap between green and red, indicating 
co-localization appeared yellow. Overall, there were not many changes in co-
localization compared with KLWT with the exception of the late endosomes, 
where KLS was localized more and KLV localization was decreased. 
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thiol-cleavable reagent on cells transfected with either KLWT or the variants.  
Differences in amounts of monomers and dimers were expressed as a ratio of 
dimers or monomers to total KL protein expressed (Figure 21).  Although not all 
trends were significant, there was a pattern of increased monomers and 
decreased dimers for both KLS and KLVS (n=3, p<0.05).  In the case of 
crosslinking, there was no significant change in the KLV variant.  Since 
crosslinking can sometimes create false interactions between proteins, Blue 
Native-PAGE was also performed to confirm the results found with this method.   
 
2.1.2 Differences in Dimerization as Shown by Blue Native PAGE  
Blue Native PAGE allows for a more natural look at alterations in 
dimerization. For this protocol, cells were transfected with KLWT or the variants 
and proteins were separated on Blue Native PAGE gels or in denaturing 
conditions by SDS-PAGE.  Running the same samples in denaturing conditions 
allowed a comparison between the amount of KL found in dimeric and 
monomeric forms to the total amount of KL in cells, even though constructs may 
not be expressed equally. While the amount of monomeric KLV was decreased 
compared to KLWT, the amount of dimerization was increased with KLV (n=3, 
p<0.05). On the other hand, expression of both KLS (n=3, p=0.06) and KLVS 
(n=3, p<0.05) showed a decrease in the dimeric form and KLVS, a significant 
increase in the monomeric form (n=3, p<0.05) (Figure 22). 
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Figure 21. Crosslinking Reveals Differences in KLVS Dimerization. To 
assess differences in KL dimerization, HEK 293 cells transfected with either 
KLWT or KL containing one or both amino acid substitutions in KLVS (V, S, or 
VS) was cross-linked using dithiobis[succinimidylpropionate.  Cross-linked 
samples were analyzed for differences in dimerization by analyzing the 
dimer/total KL protein ratio (A) Representative western blots showing 
expression of KL monomers and dimers in the absence of β-mercaptoethanol 
(BME) and total KL expression in the presence of BME. (B) Quanification of band 
intensity was measured across multiple experiments. Bar graph shows fold 
changes in monomer and dimer expression normalized to total KL expression 
(error bars are ± SEM; n=3; #p=0.06, *p<0.05, ANOVA). Data shows a decrease 
in KLV monomer and an increase in KLVS monomer as well as a decrease in KLS 
and KLVS dimers. 
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Similar to the results seen in previous experiments, the effect of the KLV variant 
is corrected by co-expression with the KLS variant. However, unlike previous 
experiments where co-expression resulted in a variant that behaved like KLWT, 
for the first time we found a distinct effect of the KLVS variant compared to 
KLWT.  When KLVS is overexpressed, more monomeric and less dimeric KL is 
found. 
 
2.1.3 Homodimerization Decreased by KLVS: Implications for Heterozygote 
KLVS Carriers 
Analysis of KLVS dimers by blue native show there is a decrease in 
dimerization, but it is not clear whether the complexes measured are 
homodimers or heterodimers. Further analysis by co-immunoprecipitation was 
used to determine whether KL’s ability to form homodimers was affected.  These 
experiments also allowed us to look at homodimers containing one KLWT and 
one KLVS allele.  Cells were transfected with combinations of KLWT and KLVS 
containing either a V5 or GFP tag.  Lysates were collected and the interaction of 
KLWT and KLVS were assessed by co-immunoprecipitation.  A GFP antibody was 
used to pull down GFP tagged KL and V5 conjugated beads were used to pull 
down V5 tagged KL.  Alternatively, separate lysates were transfected with GFP or 
V5 tagged KLWT or KLVS alone and were pulled down with the opposite 
antibody (KLV5 pulled down with GFP antibody and vice versa) in order to rule 
out 
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Figure 22. KL Variants Alter the Levels of Both Monomeric and 
Dimeric KL in Cells.    HEK 293T cells transfected with wild-type (WT) KL or 
variants (V, S or VS) were assessed for differences in dimerization using Blue 
Native PAGE. (A) Western blot illustrating differences seen in monomers and 
dimers of KL using the Blue Native-PAGE method. The single arrow points to KL 
monomers and double arrows indicate KL dimers. (B) Western blot showing total 
KL amounts in denaturing and reducing conditions. (C) Bar graph depicting fold 
change across multiple experiments in monomer and dimer formation in the KL 
variants compared to wild-type normalized to total KL levels (error bars are ± 
SEM; n=3, #p=0.06, *p<0.05, ANOVA).  KLV leads to increases in dimeric KL 
and decreases in monomeric KL while both KLS and KLVS show the opposite 
effect leading to increased monomeric and decreased dimeric KL.      
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the presence of non-specific immunoprecipitation due to antibody cross-
reactivity.  After pull-down, samples were separated by SDS-PAGE and the 
amount of interaction partner was determined by western blot analysis (Figure 
23).  By this method, we could ascertain differences in levels of dimerization 
between KLWT and KLVS either to themselves as homodimers or each other as 
heterodimers.  Results show that when compared to levels of KLWT 
homodimerization, the dimerization of KLWT to KLVS and of KLVS to KLVS are 
reduced irrespective of the antibody used to pull-down the interaction partners 
(n=3, p<0.05) (Figure 24).  The reduction in KLVS dimerization to KLVS 
confirmed the previous results from Figure 22 and suggests that the difference in 
dimerization seen may be due to the difference in homodimerization.   The 
control immunoprecipitation also shows that these results are not due to pull-
down of the opposite tag by non-specific antibody interactions (Figure 25). The 
results also expand the Blue Native findings to suggest that regardless of binding 
partner, KLWT or KLVS, KLVS dimerizes less efficiently than KLWT.      
 
2.2 KLVS Increases Heterodimerization with FGFR1c   
Changes in KL’s ability to homodimerize may impact its function alone or in 
combination with other binding partners.  We used KL’s function as a co-receptor 
with FGFR1c (285,288,291,458) as a model to determine whether the altered 
dimerization capacity of KLVS could affect protein-protein interactions.  For the 
purpose of the FGF experiments, effect of KLVS was focused on due to its  
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Figure 23. Diagram of KL-KL Co-Immunoprecipitation. Diagram 
outlining the procedures taken to assess homodimerization of KL by co-
immunoprecipitation.  Cells co-transfected with combinations of WT and/or VS 
KL with either a GFP or V5 tag were immunoprecipitated with an antibody to one 
of the tags (GFP or V5) and then probed by western blotting for presence of the 
opposite tag. This allowed for the assessment of KL interactions with other KL 
molecules coding for either WT or VS KL.  
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Figure 24. KL homodimerization is altered by the presence of the VS 
variant.    HEK 293T cells were co-transfected with combinations of wild-type 
and/or VS KL containing either a V5 or GFP tag.    Resulting lysates were 
assessed for differences in dimerization using co-immunoprecipitation (A) 
Western blot for GFP shows KLGFP pulled down by interactions with co-
expressed KLV5 variant through use of V5 beads. Non-precipitated lysate is 
shown as a control. (B) Bar graph depicting fold changes across multiple 
experiments in amount of GFP tagged KL immunoprecipitated by V5 beads 
normalized to non-precipitated lysate. (error bars are ± SEM; n=3, *p<0.05, 
ANOVA). (C) Representative western blot showing changes in pull-down of V5 
tagged KL when associated with GFP tagged KL. Non-precipitated lysate is shown 
as a control. (D) Bar graph depicting fold changes in amount of V5 tagged KL 
immunoprecipitated by GFP beads normalized to non-precipitated lysate.    
(error bars are ± SEM; n=3, *p<0.05, ANOVA). The presence of KLVS in KL 
dimers leads to an overall decrease in dimerization even if KLWT is present in the 
dimer. 
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increased physiological impact compared to KLV and KLS alone.  HEK 293 cells 
were co-transfected with KLWT or KLVS-GFP and EV or FGFR1c-V5.  Lysates 
were collected and the interaction of KL and FGFR1c was assessed by co-
immunoprecipitation.  A GFP antibody was used to pull down KLWT or KLVS 
and a V5 antibody was used to pull down FGFR1c.  To test for non-specific 
interactions, samples were also pulled down with mIgG.  After pull-down, the 
amount of co-receptor was assessed by separating the immunoprecipitated 
proteins on SDS-PAGE followed by western blot analysis for the interaction 
partner.  Amount of interaction was assessed by determining the amount of 
interaction partner precipitated, compared to the amount of interaction partner 
in the lysate.  Immunoprecipitation with either member of the complex shows an 
increase in interaction between KLVS and FGFR1c compared to KLWT and 
FGFR1c (n=3, p<0.05) (Figure 26), which was not due to non-specific antibody 
interactions (Figure 27).  These data taken together suggest that either the VS 
variant is a better binding partner for FGFR1 and/or that KL must be a monomer 
to function as a FGFR co-receptor.      
 
2.3 KLVS Increases Downstream Signaling Through FGFR1c  
Previous studies have shown that KL is necessary for FGF23 signaling through 
FGFR (285,291).  Since KLVS increases KL’s ability to interact with FGFR, it 
would be predicted to impact FGF23 signal transduction.  To assess whether 
KLVS affects FGF signaling, HEK 293 cells were transfected with KLWT or KLVS.  
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Figure 25. Control Co-immunoprecipitation of KLGFP and KLV5. In 
order to assess whether there was any non-specific pulldown between the tags 
used for co-immunoprecipiation, HEK 293 cells were transfected with either KL-
GFP or KL-V5. (A) Resulting KL-V5 lysates were pulled down with with GFP 
antibody and then were probed by western blotting for presence of KL-V5 in the 
pulldown. No non-specific pulldown of KL-V5 was seen. Non-precipitated KL-V5 
lysate is shown as control. (B) Resulting KL-GFP antibodies were pulled down 
with V5 antibody and then were probed by western blotting for presence of KL-
GFP in the pulldown. No non-specific pulldown of KL-GFP was seen.  Non-
precipitated KL-GFP lysate is shown as control. 
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After transfection, recombinant FGF23 was added to media overlaying cells.  The 
resulting lysates were separated by SDS-PAGE and analyzed for the levels of 
phosphorylated ERK (pERK) and total ERK (tERK), a kinase that is activated 
downstream of FGF23 receptor binding.  Similar to the increase in binding of 
KLVS to FGFR1c, there is also a significant increase in ERK activation as 
measured by pERK/tERK expression (n=3, p<0.01) (Figure 28A and B).  
Together these data indicate that while trafficking of the VS variant may be 
distinct from the wild-type, the most profound alteration of this polymorphism 
would be in enhancing KLVS-FGFR heterodimerization and thus FGF23 
signaling. 
 
2.4 KLVS Has Decreased Enzymatic Activity 
Arking et al. reported that the highly conserved phenylalanine at amino 
acid 352 is necessary for the glucuronidase activity of a KL paralog (442).  Using 
the fluorescent substrate, 4-methylumbelliferyl-β-D-glucuronide (4Mu-GlcU), as 
described previously (312), the enzymatic activity of shed KLWT or KLVS 
concentrated from serum-free media removed from the KL980 stable cells or 
concentrated serum-free media of HEK293 non-transfected cells (EV) was 
assessed.  Before assaying enzymatic activity, the concentrated media was 
analyzed by western blot to determine KL protein concentration and the amount 
used in the assay was corrected based on these results (Figure 29A).  To 
investigate the enzymatic activity of KLWT and KLVS, the concentrated KL was  
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Figure 26. KLVS enhances interaction with FGFR1c. HEK 293T cells 
transiently transfected with FGFR1c-V5 (FGFR) and either empty vector (EV), 
wild type (WT) or mutant (VS) KL with (C-D) or without (A-B) a GFP tag. (A) 
Western blot showing samples that were pulled down with V5 beads to isolate 
FGFR1c-V5 and probed for KL presence. Ten percent of IP was probed for FGFR-
V5 presence to show equal immunoprecipitation. (B) Bar graph depicting fold 
change across multiple experiments in immunoprecipitation of KL normalized to 
lysate (error bars are ± SEM; n=3, *p<0.05). (C) Western blot of representative 
samples that were pulled down with GFP beads to isolate KL and probed for 
FGFR1c-V5 presence. Ten percent of IP was probed for KL presence to show 
equal immunoprecipitation (* marks non-specific band seen in EV transfection). 
(D) Bar graph depicting fold change across multiple experiments in 
immunoprecipitation of FGFR1c-V5 normalized to lysate (error bars are ± SEM; 
n=3, *p<0.05). 
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Figure 27. Control Co-immunoprecipitation Shows No Non-Specific 
Pulldown of FGFR1c/KL Complex.  HEK 293T cells were transiently 
transfected with FGFR1c-V5 (FGFR) and either empty vector (EV), wild type 
(WT) or mutant (VS) KL-GFP. (A) Western blot showing samples that were 
pulled down with mIgG and probed for KL-GFP presence. Blot shows no non-
specific pulldown of KL-GFP. Non-precipitated lysate samples shown as control. 
(B) Western blot showing samples that were pulled down with mIgG and probed 
for FGFR1c-V5 presence. Blot shows no non-specific pulldown of FGFR1c-V5. 
Non-precipitated lysate samples shown as control. 
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incubated with a series of 4Mu-GlcU concentrations ranging from 0.1 to 15 µM 
and fluorescence was measured at 30-minute intervals for 2.5 hours. The 
concentration of product was plotted over reaction time for EV, KLWT and KLVS 
and the initial velocity (v0) of each reaction was determined for every initial 
substrate concentration ([S0]) by calculating the slope of the resulting graphs 
(Figure 29 B and C). [S0] and v0 were then plotted to obtain the Lineweaver-
Burke plot for the samples (Figure 18D).  From this plot, the Km and vmax were 
calculated.  While the Km for WT (4.44 ±0.956) and VS (6.09±1.55) do no 
significantly differ, the Vmax of VS (0.227) is significantly lower than KLWT 
(0.613) (n=3, p<0.01) (Figure 29D).  This suggests that the VS variant does not 
change the ability of KL to bind to its substrate, but instead alters the enzyme’s 
capacity to cleave its product. 
In order to determine whether the activity seen was due to KL specific 
enzymatic activity, KL980 samples were concentrated as in the previous 
experiments, but then were incubated with V5 sepharose beads.  Incubation with 
V5 sepharose beads allowed for immunodepletion of KL from the media due to 
the V5 tag on the C-terminus of the KL construct.  The level of immunodepletion 
was measured by western blot analysis and was compared to non-
immunodepleted samples (Figure 30A).  Although depletion of KL was not 
complete, the depletion was significant.  After immunodepletion, the media were 
analyzed for enzymatic activity as described above.  Depletion of KLWT led to a 
significant decline in enzymatic activity, however, the depletion of KLVS did not  
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Figure 28. KLVS enhances FGF23 signal transduction.  HEK 293T cells 
transiently transfected with KLWT or KLVS were treated with FGF23 to activate 
FGFR1c signaling. (A) Representative western blot showing differences in ERK 
phosphorylation compared to total expression of ERK after transfection of KLWT 
or KLVS. (B) Bar graph depicting fold change across multiple independent 
experiments in ERK phosphorylation normalized to total ERK expression (error 
bars are ± SEM; n=3, *p<0.05).    
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have any effect (n=3) (Figure 30B).  Interestingly, immunodepletion increased 
the background of the experiment as measured by immunodepletion of EV 
media.  The increase background could be due to residual V5 beads in the media, 
which could give false absorbance readings.  Overall, these data show that the 
activity seen is specific KL enzymatic activity.  If the increase in background is 
taken into consideration, the level of depletion achieved for KLWT in this 
experiment may be enough to totally abolish the enzymatic activity seen.  This 
finding also confirms that the decreased enzymatic activity of KLVS is due to the 
specific actions of KL and not another glucuronidase found in the media. 
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Figure 29. KLVS Leads to Decreased Enzymatic Activity. Media 
concentrated from HEK2 293 cells stably transfected with KLWT980 or 
KLVS980 or EV were (A) run on a western blot to determine approximately equal 
concentration of KL in the two variant samples. KLWT and KLVS were incubated 
with a series of 4Mu-GlcU concentrations ranging from 0.1 to 15 µM and 
fluorescence was measured at 30-minute intervals for 2.5 hours.  The 
concentration of product was plotted over reaction time for EV, (B) KLWT and 
(C) KLVS.  The slope of the resulting graphs were calculated to determine initial 
velocity (v0) for each initial substrate concentration ([S0]). (D) The resulting v0 
were plotted against the [S0] to obtain the Lineweaver-Burke plot.  From this 
plot, the Km and vmax were calculated.  While the Km did not differ between KLWT 
and KLVS, the vmax of KLVS was significantly lower (n=3, p<0.05).   
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Figure 30. Immunodepletion of KL Eliminates KL Specific Enzymatic 
Activity. Media concentrated from HEK2 293 cells stably transfected with 
KLWT980 or KLVS980 or EV were immunodepleted with V5 sepharose beads to 
remove KL from the media. (A) Resulting samples were run on western blot to 
determine the efficiency and equality of KL depletion between KLWT and KLVS. 
Non-immunodepleted samples are shown as a control. (B) The samples were 
then incubated with a series of 4Mu-GlcU concentrations ranging from 0.1 to 15 
µM and fluorescence was measured at 30-minute intervals for 2.5 hours. After 
determining v0, it was plotted against [S0] to obtain the Lineweaver-Burke plot.  
From this plot, the Km and vmax were calculated. There was a significant decrease 
in the vmax of the depleted KLWT compared to the non-depleted control (n=3, 
p<0.05). Between the depleted samples, there was no difference in vmax 
suggesting that the specific activity of KL is depleted.  
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CHAPTER IV: DISCUSSION 
1. KLOTHO AND AGING 
The KL protein has gathered a lot of interest from members in the aging 
field since its discovery 16 years ago due to the close approximation of KL 
deficient mice phenotypes to normal human aging. Not only does lack of KL lead 
to a shortened lifespan, but the phenotypes leading up to this decrease in lifespan 
resemble many of the diseases that are prevalent in aging populations.  KL’s 
organism-wide aging effects are made more interesting by the systems it has been 
shown to regulate. Many of the functions attributed to KL overlap with pathways 
and systems that have been independently associated with theories of aging.  As 
concluded previously, there is not one current theory of aging that completely 
encompasses the complexities that lead to aging organisms.  KL’s ability to 
modulate pathways and systems implicated by multiple theories including 
oxidative stress, inflammation, senescence, growth factor signaling and pituitary 
function adds to that argument suggesting that a dysregulation of multiple 
different pathways leads to aging.  How one molecule is able to have such diverse 
effects is still not sufficiently elucidated, but it is clear that it has an overarching 
regulatory role in many systems and pathways that are intricately linked with the 
aging process. 
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2. KLOTHO POLYMORPHISMS  
Analysis of KL polymorphisms gives insight into how the protein that 
causes such a drastic phenotype in mice may affect human longevity and risk of 
disease.  Many polymorphisms have been identified by Genome Wide Association 
studies (GWAS) in both coding and non-coding regions of KL that are associated 
with increased risk of disease.  Despite the plethora of polymorphisms, only a 
handful have been associated with changes in KL function or KL levels.   
One polymorphism, the KLVS has not only been associated with increased 
disease risk, but has also been associated with alterations in longevity.  A few 
studies on this variant have also suggested it may alter the function of KL.  
Transfection of the KL1 domain into HeLa cells showed that KLV leads to a 
decrease in secretion while the expression of KLS and the combination of both 
SNPs led to an increase in secretion (442).  This study also showed that the 
F352V substitution alone led to a decrease in the enzymatic activity of KL1 
through measuring the activity of a KL paralog with a corresponding amino acid 
substitution (442).  However, the use of the KL1 domain is non physiologic as 
KL1 is only detected at the mRNA level and has been identified as a target for 
nonsense-mediated mRNA decay by the National Center for Biotechnology 
Information (NCBI) (reference sequence: NM_153683.2) (459). A second study 
examining KLVS mechanism also showed that the full-length KLV variant did not 
have the same growth inhibitory effect as KLWT in breast cancer cells (447).  
While this study again suggests there is a functional difference in the variant, it 
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only looked at the V substitution alone and not KLVS, which is more 
physiologically relevant.  Both of these studies suggest that KLVS may cause a 
functional difference in the protein, but are limited by the constructs used. This 
prompted a more thorough study of the KLVS and resulting substitutions to 
better understand how they may lead to changes in longevity and disease risk. 
 
3. ALTERATIONS IN PROCESSING OF KLVS ISOFORMS 
3.1 KLV Expression Leads to Altered KL Processing 
Maintaining proper trafficking and shedding of KL is important for 
maintenance of function.  Many KL functions rely on the far-reaching effects of 
the extracellular domain that is cleaved from full-length KL at the plasma 
membrane.  Altering the shedding of KL would alter the ability of KL to exert its 
humoral-like effects.  The importance of KL shedding is emphasized by the rescue 
of age-related phenotypes in KL deficient mice by undergoing parabiosis with 
wild-type mice (278).  Rescue of KL expression limited to brain and testes was 
also capable of rescuing almost all of the age-related phenotypes in KL deficient 
mice (198) further emphasizing the importance of KL shedding into blood and 
CSF (230).  The importance of KL shedding coupled with previous studies 
suggesting KLVS secretion may be altered led to the current studies that sought 
to further elucidate how KLVS alters processing and the implications it may have 
for KL function. 
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In this thesis, investigations of KLVS processing showed that KLV, but not 
KLVS led to alterations in shedding of full length KL, which seem to be 
dependent on trans golgi processing due to the attenuation of this phenotype in a 
construct lacking the intracellular and transmembrane domain. Further analysis 
of the KLV processing revealed that the decrease in shedding was paired with a 
decrease in half-life indicating the reason for the decreased amount of shedding 
could be due to increased rate of degradation of the KLV.  It was first 
hypothesized that the decreased KLV shedding and half-life could be explained 
by misfolding of the protein. Despite this connection, shedding is only weakly 
correlated with the changes in half-life, suggesting there may be a second factor 
that connects these two similar changes (Figure 31). Treatment with two different 
chemical chaperones that are known to decrease levels of misfolded proteins was 
not able to rescue the KLV phenotype.  Glycerol treatment had no effect on KLV 
shedding, while treatment with MT-1, a small molecule chemical chaperone, 
increased shedding equally in both KLWT and KLV suggesting that its effect was 
not specific to the phenotype seen with KLV.  Since alterations in processing 
could explain both decreased shedding and half-life, we decided to examine 
whether there are alterations in membrane localization of the variants.  These 
experiments showed that there was a decrease in KLV localization to the 
membrane that could be blocked by inhibiting dynamin-dependent endocytosis.  
This result suggests that the decrease in membrane localization is caused by 
increased endocytosis of the KLV variant.   
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Figure 31. Correlation Between Shedding and Half-life Changes in KL 
Variants. Mean values from full-length shedding experiments were plotted on 
the x-axis against half-life values calculated for the same variants. GraphPad 
Prism was used to calculate the line of best fit and whether the slope of the line 
significantly differed from 1. There was no significant correlation between 
shedding and half-life (r2=.1035, p=.2244). 
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Increased endocytosis, which would lead to trafficking to endosomes followed by 
lysosomal degradation, could explain the decrease in half-life.  An increase in 
KLV endocytosis could also explain the decrease in shed KL because less would 
be present at the membrane, which is the site of KL sheddases, ADAM10 and 
ADAM17.  Due to the alterations in endocytosis, the variants were co-transfected 
with SORLA, which is a protein known to aid in trafficking of endocytosed 
proteins. It was hypothesized that SORLA may be able to direct the endocytosed 
KLV towards the recycling pathway where it would return to the trans golgi 
network instead of getting degraded by the lysosomes.  If SORLA could 
accomplish this, it would rescue the phenotype seen in KLV.  Unfortunately, 
SORLA did not lead to a significant difference in KLV shedding suggesting that it 
was not able to rescue the endocytosed KL.  This does not rule out the possibility 
that the phenotype seen in KLV is due to alterations in endocytosis, but does 
suggest that KL is not a substrate for SORLA.   
Since proper shedding is necessary for functioning KL, a luciferase assay 
was designed to screen for modulators of KL shedding.  This assay was able to 
confirm the effect of insulin on the shedding of KL and demonstrated that IGF-2 
can also increase the amount of KL shed from the plasma membrane.  These 
results could be used to find other modulators of KL shedding, which would not 
only be useful for targeting diseases in which plasma KL is decreased, but could 
also lead to a better understanding of the mechanisms of KL shedding regulation.  
These compounds could also be screened for an ability to correct the KLV 
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decrease in shedding, which could lead to a better understanding of how the KLV 
alters the shedding and trafficking of KL.  
Although KLV leads to alterations in trafficking, analysis of the subcellular 
localization of the variants does not show much difference.  This could be due to 
the insensitivity of the assay or because it is only looking at a frozen moment in 
time so the cell dynamics cannot be seen.  While there is no striking difference in 
subcellular localization there is a small difference in the amount of KL seen in the 
late endosomes stained with mannose-6-phosphate (M6P).  Compared to KLWT 
expression, KLV co-localizes less to the late endosomes.  The decrease of KLV in 
the endosomes is contrary to what might be expected due to the increase in KLV 
endocytosis.  This may be due to a faster rate of KLV processing into the 
lysosomes where it is degraded.  The increase in KLS could be due to an increased 
amount being packaged into microvesicles called exosomes that form in the late 
endosomes.   Exosomes in the urine have been shown to contain KL suggesting 
that KL may be secreted into the extracellular milieu in this fashion (453).  
 
3.2 KLS Alters Endosomal Trafficking 
Despite the large differences seen in KLV trafficking, the trafficking of KLS 
mostly trends with wild type.  The one exception is the apparent link to 
alterations in endosomal trafficking. Not only do immunofluorescence studies 
suggest that KLS has an increased localization to the late endosomes, but 
membrane localization studies also show that KLS has an increased presence on 
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the plasma membrane that is attenuated by inhibition of endocytosis.  Together, 
this data suggests that retromer trafficking of KL from the endosomes back to the 
plasma membrane via the trans-golgi network is important for proper KL 
trafficking.  It is possible that KLS leads to other alterations in shedding and 
trafficking that were not detectable with the power of this study.  
  
3.3 Intragenic Complementation of KLV and KLS Result in Like 
Normal KLVS Processing 
The relative lack of KLVS trafficking phenotype suggests that expression of 
the S substitution in the presence of the V substitution is able to correct for the 
alterations in trafficking due to intragenic complementation.  This could be 
through increased trafficking of KL containing the S substitution from the 
endosomes back to the plasma membrane as is suggested from the differences 
seen in KLS endosomal trafficking.  This complementation is similar to cases of 
mut-0 methylmalonic aciduria where one substitution is able to rescue the 
aberrant phenotype caused by another substitution (460). Despite being able to 
rescue KLV aberrant trafficking, the association of KLVS with disease risk 
suggests that there are other functional changes that the KLS is not able to 
rescue.  This led to further investigation in Aim 2 of how the KLVS may lead to 
alterations in KL function. 
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4. KLVS VARIANT ALTERS KL FUNCTION 
4.1 KLVS Decreases Homodimerization 
Despite normal trafficking of the KLVS, expression of the polymorphism 
in humans leads to increased risk of disease suggesting that KLVS leads to 
alterations in protein function independent of processing alterations. In an 
attempt to try to explain why KLVS would change protein function, we first 
looked at dimerization of the variants.  Dimerization is often necessary for proper 
trafficking and function of transmembrane proteins (454) and KL is known to 
form dimers or higher oligomers in the blood and CSF of mice and humans as 
well as in conditioned media from cells overexpressing KL (230,231).  This makes 
it plausible that the KLVS variant may lead to differences in dimerization, which 
could explain the alterations in function.  Further evidence of a possible role of 
dimerization in the actions of KLVS was provided by analysis of KL using 
disulfide bond prediction software, DIANNA (461).  This software predicted that 
the cysteine changed to a serine in the S substitution is involved in an 
intramolecular disulfide bond.  Given the fact that cysteines are known to be 
important for the formation of disulfide bonds, which are critical in proper 
folding of proteins (462) and can play crucial roles in dimerization (463-466) 
analysis of KLVS dimers seemed like a good starting point.   
Both crosslinking and Blue Native gel analysis of dimerization showed that 
KLS and KLVS lead to decreases in dimerization, however the increase in KLV 
dimerization was only seen by Blue Native electrophoresis.  Because of the 
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artificial cross-linking of bonds involved in the first technique, the results 
gathered from Blue Native separation are deemed to be more accurate 
representations of KL dimerization.  Based on the Blue Native gel results, the 
increase in KLV dimerization coupled with decreased KLS and KLVS 
dimerization suggests that KLS attenuates the KLV phenotype by correcting for 
the increase in dimerization.  Although the KLS induced decrease in dimerization 
corrects the aberrant trafficking caused by the V substitution, the KLVS still has 
altered dimerization suggesting it has altered function.  This is the first difference 
attributed to the KLVS variant.  Previously all results have shown changes in KLV 
or KLS alone, but when combined they have led to a protein that behaves like 
KLWT.  Since KLVS is the variant found in humans, finding a functional 
difference in this variant is necessary for understanding how the VS affects risk of 
disease.   
This difference in dimerization could also help explain the alteration in 
endocytosis that is seen with the KLV.  Although it is unlikely that the V 
substitution in the extracellular N-terminus of the protein has a direct role in 
controlling endocytosis, it is possible that the KLV increase in dimerization could 
be a signal for internalization leading to the altered trafficking of KLV. It is 
known that KL interaction with other proteins, namely the TRPC1-VEGFR2 
complex is able to increase the internalization of the complex showing that is 
capable of regulating endocytosis.  This would further explain how the KLS  
 149 
 
 
Figure 32. Shedding and Dimerization Changes in KL Variants are 
Inversely Correlated.  Mean values from full-length shedding experiments 
were plotted on the x-axis against mean values of dimer/total calculated for the 
same variants. GraphPad Prism was used to calculate the line of best fit and 
whether the slope of the line significantly differed from 1. There was a significant 
correlation between shedding and dimerization (r2=.6978, p=.0007). 
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variant decrease in dimerization could correct for the alteration in KLV shedding 
by inhibiting the increase in dimerization.  It is also possible that 
homodimerization of KL inhibits retromer trafficking to the plasma membrane, 
which would explain the opposite effect of KLV and KLS on plasma membrane 
localization and why both effects are inhibited by expression of dominant 
negative dynamin.  These speculations are bolstered by analysis of associations 
between dimerization and shedding (Figure 32) and dimerization and half-life 
(Figure 33). Both analyses suggest that changes in dimerization are inversely 
correlated with these two measures of changes in KL processing, further 
implicating a role in dimerization in the control of KL processing. 
To confirm the difference in KLVS dimerization with a more quantitative 
method and to expand upon these findings, co-immunoprecipitation studies were 
performed.  These experiments allowed us to look at the dimerization of KLWT to 
itself in the presence or absence of the KLVS variant.  These results showed that 
the decrease in KLVS dimerization persists even when there is one molecule of 
KLWT in the dimer.  It is possible that with extra power added to the experiment, 
the decrease in dimerization seen with VS:VS dimers might be greater than that 
seen with WT:VS dimers, but in this study there was no significant difference 
between the two.  This suggests that differences in disease risk seen between 
heterozygous and homozygous expressors of KLVS are not due to variances in 
dimerization, however it does show a change in function of the KLVS for the first 
time.  
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Figure 33. Half-Life and Dimerization Changes in KL Variants are 
Inversely Correlated. Mean values from half-life experiments were plotted on 
the x-axis against mean values of dimer/total calculated for the same variants. 
GraphPad Prism was used to calculate the line of best fit and whether the slope of 
the line significantly differed from 1. There was a significant correlation between 
shedding and dimerization (r2=.6548, p=.0014). 
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Overall these findings suggest that despite the correction of trafficking, the KLVS 
variant may still have altered function through altered protein-protein 
interactions. 
 
4.2 KLVS Increases Heterodimerization with FGFR1c  
KL’s interaction with FGFR as a co-receptor for FGF23 binding is the most 
well studied KL protein-protein interaction and is critical in proper kidney 
function (467,468). KL activity as an FGF co-receptor is vital to many of the 
hallmark functions of KL as suggested by the similarities of the KL-/- and FGF23 
-/- mice (291).  Drastic changes in KL’s ability to bind to FGFR can also lead to 
devastating illness (H193R) further emphasizing the significance of KL-FGF 
function (469).  Because of the importance of FGF signaling in KL function, we 
decided to determine whether KLVS would alter interaction with FGFR and thus 
affect its subsequent FGF23 signaling cascade.  Contrary to the reduced ability of 
KLVS to bind other KL molecules, the ability of KLVS to bind FGFR1c is 
increased.  This suggests that the increased presence of KL monomers in carriers 
of KLVS leaves more KL free to bind to FGFR increasing the amount of KL-FGF 
complexes that form.  This implies that αKL may behave much like βKL, which 
binds with the FGFR signaling complex as a monomer (470). These results 
indicate that the KLVS variant leads to alterations in KL’s ability to act as a co-
receptor. 
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To further elucidate KLVS’s effect on the FGFR signaling complex, we 
tested whether there was a difference in KLVS’s ability to activate signaling 
downstream of the complex.  Since previous studies have shown that KL is 
necessary for downstream ERK activation via FGF23 (285,291), we wanted to 
determine whether KLVS would alter the amount of downstream ERK 
phosphorylation.  In line with the changes in binding, we found that KLVS also 
leads to an increase in downstream ERK activation.  This significant increase in 
ERK activation could explain the differences seen between heterozygosity for 
KLVS versus homozygosity.  In heterozygous individuals, the small increase in 
FGF23 signaling could be beneficial, as seen by the many protective effects of the 
FGF23-KL axis. This could lead to the advantageous effects of KLVS 
heterozygosity.  While a small increase can be beneficial for heterozygous 
individuals, homozygous individuals would have a larger increase in FGF23 
signaling which could lead to detrimental health effects such as 
hypophosphatemia, aberrant vitamin D metabolism, impaired growth and 
rickets/osteomalacia (471).  These changes in health could lead to the increased 
risk of disease found in homozygous individuals.  Hypophosphatemia, for 
example, has been linked to both cardiovascular disease and metabolic syndrome 
(472), which have both been associated with KLVS homozygosity 
(435,441,443,444).  These findings suggest there is a fine line between a 
beneficial increase in FGF23 signaling versus a detrimental increase illustrated 
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by the differences in individuals heterozygous for KLVS versus homozygous 
individuals  
 
4.3 Effect of KLVS on Enzymatic Activity of KL 
 Previous studies have shown that a homolog of KLV has reduced 
glucosidase activity and evidence from other glucosidases show that many 
enzymes from this family form homo or heterodimers that are necessary for their 
enzymatic activity (473-475).  This led us to conclude that the KLVS may change 
the ability of KLVS to act as an enzyme due to its changes in dimerization. 
Analysis of the enzymatic activity of KLVS did show that there was a reduced 
enzymatic activity of KLVS.  Immunodepletion of KL from the media also 
confirmed that this activity was due to the presence of KL in the concentrated 
media.  These findings are necessary for understanding the effect of KLVS 
because the enzymatic activity of KL is important for its regulation of ion channel 
membrane localization.  This suggests that KLVS might also lead to alterations in 
the membrane localization of ion channels regulated by KL, which could affect KL 
dependent ion homeostasis.  Further studies could investigate whether KLVS has 
a decreased ability to alter localization of ion channels such as TRPV5. 
 
5. SUMMARY 
In humans the KLVS polymorphism is the result of a collection of 6 SNPs 
that always occur together.  The current studies focused on the two SNPs that 
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lead to amino acid changes.  We show alterations in shedding and processing but 
the effects are small overall and intragenic complementation may further 
minimize these effects in vivo. Despite the ability of intragenic complementation 
to allow proper trafficking of the VS variant, we have identified for the first time, 
KLVS specific changes in KL function, namely differences in the protein-protein 
interactions as illustrated by the dimerization and FGFR1c interaction and 
signaling experiments and alterations in KL enzymatic activity as shown through 
β-glucuronidase assays.  Although we have identified clear KLVS changes, it is 
likewise possible that the four other SNPs contribute to disease risk in ways we 
have not appreciated.  As the SNPs are near the intron/exon borders, splicing or 
splicing efficiency could be affected by the SNPs.  A small decrease in proper 
splicing coupled to dimerization or other protein binding changes could 
compound to create a bigger problem than presently appreciated.  
 
6. FUTURE DIRECTIONS 
The research described in this thesis has provided insight into how the 
KLVS variant affects the function of KL, but much more could be ascertained 
about how the VS variant leads to the increased risk of disease.  More 
information could be gathered about the role of dimerization in the shed form of 
KL.  As mentioned previously, KL is found as a dimer in the blood and CSF (230) 
suggesting dimerization may be important for its humoral functions.  Studies 
could investigate whether the reduced dimerization of KLVS has an effect on the 
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half-life of the shed protein and could investigate whether it has an effect on the 
other functions that have been ascribed to the shed form of the protein. Further 
studies could also analyze more in-depth into how the KLVS alters FGF23 
signaling.  Studies have shown that KL is able to protect against vitamin D 
induced apoptosis through its regulation of FGF23 signaling (476) so it is 
possible that KLVS has a higher ability to protect against this.  Since this is 
through KL’s inhibition of 1-α-hydroxylase, the enzyme responsible for synthesis 
of the active form of vitamin D, levels of this enzyme could also be analyzed as 
well as other downstream proteins regulated by KL such as Egr-1.  Evidence from 
the enzymatic assay performed also suggests that the VS variant may affect KL’s 
ability to regulate membrane localization of ion channels.  As mentioned 
previously, future studies could assess the effect of KLVS on the localization of 
TRPV5 as well as other ion channels known to be affected by KL.   
 
7. CONCLUDING REMARKS 
In this study, the effect of the KLVS variant on trafficking and function of 
KL has been studied.  Through this investigation, we have determined that KLV 
has altered trafficking leading to a decrease in the amount of KL shed from the 
membrane as well as a decrease in half life.  This aberrant processing caused by 
the KLV variant can be attenuated by co-expression of the KLS substitution 
suggesting there is intragenic complementation between the two substitutions.  It 
is possible that the ability of KLS to rescue the KLV phenotype is through its 
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inhibition of dimerization.  When expressed together in the VS variant, the 
increase in dimerization seen with the V variant is attenuated and in fact 
reversed.  This reversal of dimerization could be the reason for the amelioration 
of the processing phenotype seen in the KLVS variant suggesting that it is the 
increase in dimerization that causes the increased endocytosis and other related 
phenotypes.  The alteration in dimerization is also linked to the changes seen in 
FGFR signaling as well as the decrease in enzymatic activity highlighting the 
effects of KLVS on dimerization as the key difference leading to the other 
functional alterations seen (Figure 34).  Overall, this research has shown the first 
effect of the KLVS isoform on KL function giving insight into how this 
polymorphism may affect risk of age-related disease. 
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Figure 34. Interactions of Different KL Functions on the Plasma 
Membrane.  Diagram showing the interactions of various KL functions that are 
altered by the KLVS variant. (A) KL dimerization, which is decreased by the 
KLVS variant mediates the amount of KL endocytosed and degraded. Increased 
endocytosis, as seen by KLV, leads to an increase in degradation leading to less 
KL available on the plasma membrane where it can be (B) cleaved by ADAM10/17 
leading to the shedding of the extracellular domain (extracell. KL) into the media. 
(C) Alternatively, as a monomer, KL can also participate in formation of 
heterodimers such as the one with FGFR1c. This heterodimer leads to FGF23 
binding to FGFR and initiates downstream signaling. Together, this shows how 
regulation of KL dimerization can lead to regulation of other KL functions.  
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